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GlutathioneCystic ﬁbrosis is a lethal autosomal recessive condition caused by a defect of the transmembrane conductance
regulator gene that has a key role in cell homeostasis. A dysfunctional cystic ﬁbrosis transmembrane conduc-
tance regulator impairs the efﬂux of cell anions such as chloride and bicarbonate, and also that of other solutes
such as reduced glutathione. This defect produces an increased viscosity of secretions together with other met-
abolic defects of epithelia that ultimately promote the obstruction and ﬁbrosis of organs. Recurrent pulmonary
infections and respiratory dysfunction are main clinical consequences of these pathogenetic events, followed by
pancreatic and liver insufﬁciency, diabetes, protein-energy malnutrition, etc. This complex comorbidity is asso-
ciated with the extensive injury of different biomolecular targets by reactive oxygen species, which is the bio-
chemical hallmark of oxidative stress. These biological lesions are particularly pronounced in the lung, in which
the extent of oxidative markers parallels that of inﬂammatory markers between chronic events and acute exac-
erbations along the progression of the disease. Herein, an abnormal ﬂux of reactive oxygen species is present by
the sustained activation of neutrophils and other cystic ﬁbrosis-derived defects in the homeostatic processes of
pulmonary epithelia and lining ﬂuids. A sub-optimal antioxidant protection is believed to represent a main con-
tributor to oxidative stress and to the poor control of immuno-inﬂammatory pathways in these patients. Ob-
served defects include an impaired reduced glutathione metabolism and lowered intake and absorption of
fat-soluble antioxidants (vitamin E, carotenoids, coenzyme Q-10, some polyunsaturated fatty acids, etc.) and
oligoelements (such as Se, Cu and Zn) that are involved in reactive oxygen species detoxiﬁcation by means of
enzymatic defenses. Oral supplements and aerosolized formulations of thiols have been used in the antioxidant
therapy of this inherited disease with the main aim of reducing the extent of oxidative lesions and the rate of
lung deterioration. Despite positive effects on laboratory end points, poor evidence was obtained on the side
of clinical outcome so far. These aspects examined in this critical review of the literature clearly suggest that fur-
ther and more rigorous trials are needed together with new generations of pharmacological tools to a more ef-
fective antioxidant and anti-inﬂammatory therapy of cystic ﬁbrosis patients. This article is part of a Special Issue
entitled: Antioxidants and Antioxidant Treatment in Disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Cystic ﬁbrosis (CF) is a lethal autosomal recessive disorder caused
by a single gene defect. This was identiﬁed in 1989 to map on the
chromosome 7 and to correspond to the gene coding for the trans-
membrane conductance regulator (CFTR) that is mainly expressedxidants and Antioxidant Treatment
Fibrosis” of the Italian Society for C
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l rights reserved.in the apical membrane of epithelial cells that line mucous mem-
branes and submucosal glands [1]. Several mutations have been
identiﬁed to cause this gene defect with the Phe508del, or ΔF508,
as one of the most common mutations in Caucasians. The prevalence
at birth varies in the different regions according with ethnic back-
ground, from roughly 1 in 3000 white Americans and northernin Disease.
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ses based on the type of defect caused on CFTR protein metabolism
and function. Several physiological processes affected by these muta-
tions are related to the role of CFTR as anion channel. This mainly
regulates chloride efﬂux, but other and larger anions such as reduced
glutathione cross the plasmalemma throughout this transmembrane
protein widely expressed in diverse epithelial tissues. Other ion
transport systems are under its inﬂuence, such as bicarbonate
anion and sodium channels, so that a defective CFTR can impair
several processes such as cell volume and pH regulation, transepithe-
lial transport, membrane conductance, and the GSH-related antioxi-
dant and detoxiﬁcation activity in the extracellular milieu [2,3].
CFTR dysfunction is associated with an altered ﬂuid and electrolyte
composition of secretions, their increased viscosity and progressive
obstruction and ﬁbrosis of organs [4]. The severity of these CF symp-
toms varies independently of the type and number of mutations
diagnosed, suggesting that CFTR gene and its mutations interact
with other genes at the transcriptional and post-translational level
to inﬂuence a wide series of physiological processes. Lung, pancreas
and liver are severely affected by these events, and recurrent infec-
tions of the airways together with pancreatic insufﬁciency and diabe-
tes are most common conditions secondary to CF [1].
The presence of a defective CFTR appears to produce a redox im-
balance in epithelial cells and extracellular ﬂuids and to cause an ab-
normal generation of reactive oxygen species (ROS). A constitutive
defect of GSHmetabolism together with a lowered intake and absorp-
tion of fat-soluble antioxidant vitamins (vitamin E and carotenoids)
could contribute to a defective antioxidant protection, which is be-
lieved to exacerbate oxidative stress indices along with the progres-
sion of clinical status [5–7]. The development of inﬂammatory and
degenerative lesions in target tissues such as lung, pancreas and
liver further exacerbate the shift from normal to abnormal ﬂux of
ROS in several organs, thereby leading to develop systemic oxidative
stress. This is a chronic-degenerative trait common to other and
severe inﬂammatory diseases such as chronic kidney disease and
some auto-immune syndromes (reviewed in [8,9]), which mayFig. 1. Oxidative unbalance in conductive airways of patients affected by cystic ﬁbrosis. airw
reactive oxygen species (ROS), 2. lowered levels of glutathione (GSH) and 3. reduced nitric o
of both neutrophils and bronchial epithelial cells, contributes to the progressive lung tissue
characterized by the release of chemokines and cytokines (e.g. IL-8 and IL-6, respectively). N
IL, interleukin.conspire with further mechanisms to worsen the prognosis of this
inherited disorder (recently reviewed in [10]).
In view of these aspects, the CF patient is assumed to have a higher
antioxidant demand. This has provided the rationale for the systematic
investigation of antioxidant levels in blood and targeted tissues of CF
patients, mainly the epithelium and lining ﬂuids of the airways, and
to plan for antioxidant interventions that might rescue speciﬁc defects
of these patients. These also include the use of anti-inﬂammatory
agents and nutritional formulations which can produce an “antioxi-
dant effect”, i.e. the lowering of oxidative stress indices, as a result of
their direct or indirect action. Despite a number of promising in vitro
and pre-clinical observations, antioxidants used as oral supplements
or directly administered in the CF airways have failed to provide con-
vincing evidence at the clinical level. Future efforts are required to iden-
tify more advanced agents and therapeutic strategies thatmay enhance
secondary prevention and chemotherapy of airway inﬂammation and
oxidative stress in CF patients. Advances in the approaches capable of
improving nutritional status and antimicrobial therapy are of main
relevance to further ameliorate quality of life and survival rates in CF.
These aspects will be discussed in this manuscript with the aim of
providing an updated review of the literature as well as of strategies
and future directions of antioxidant therapies in CF patients.
2. Inﬂammatory pathways and oxidative stress in CF
2.1. Progressive inﬂammatory damage in CF lungs and the contribution
of oxidants
Evidence supporting the occurrence of oxidative stress in CF is by
now established and extensive [6,10–12]. As introduced above, CF-
related defects of the pulmonary epithelium and a sustained PMN
activation by recurrent infections create the conditions for an abnor-
mal ﬂux of reactive oxygen species (ROS) in the CF lung (Fig. 1) be-
tween events of acute and chronic inﬂammation. Abnormalities of
markers of ROS activity and inﬂammation are most evident during
acute respiratory exacerbations and show improvement with theay surface liquid (ASL) in CF bronchi is characterized by 1. increased concentration of
xide (NO). The net increase of pro-oxidative species in ASL, as a result of derangements
damage and to the ampliﬁcation of the inﬂammatory response in CF airways. This is
OX, NADPH oxidase; MPO, mieloperoxidase; DUOX, dual oxidase; LPO, lactoperoxidase,
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successful therapy of infection do not normalize these markers dem-
onstrates the presence of a chronic inﬂammatory syndrome that is
intrinsic to the CF defect. In this context, ROS may lose their physio-
logical role in the killing of pathogens, to turn into toxic effectors re-
sponsible for the damage of the pulmonary epithelium as well as of
other components of the lung parenchyma and lining ﬂuids. Impor-
tantly, ROS can modify the thiol homeostasis of extracellular ﬂuids
and epithelia [16] and promote the activation of MAPK signaling
pathways [17], which regulate both the NFkβ-dependent and
-independent transcription of pro-inﬂammatory genes and other mo-
lecular effects associated with the immuno-inﬂammatory imbalance
observed in the CF lung.
Hallmark of the chronic inﬂammatory lung disease in CF is the
release of chemokines, mainly interleukin (IL)-8 [18,19], leading to
the neutrophil recruitment in the bronchial lumen (see [20] for a
review). Whether CF lung inﬂammation arises independently and
before bacterial infection remains to be fully established, although
IL-8 and pro-inﬂammatory cytokines have been found in bronchoal-
veolar lavage ﬂuids of CF infants even before the onset of an overt
bacterial infection [21]. Although directed against infective agents,
the chronic inﬂammation in CF lungs is largely recognized as mainly
responsible for the progressive tissue damage leading to respiratory
insufﬁciency. Dissection of the pathophysiology of CF chronic lung
inﬂammation should take into account the bronchial epithelial cells
expressing the mutated CFTR protein, the polymorphonuclear neu-
trophils recruited into the bronchial lumens and the bacterial infec-
tion itself, with special regards to Pseudomonas aeruginosa, the most
common gram negative microorganism which colonizes CF airways
[22]. Thus, novel anti-inﬂammatory therapies against the progressive
damage of the CF respiratory tissue should be mainly aimed i) to re-
duce the excessive recruitment of neutrophils, by intervening on the
transmembrane signaling pivoting the excessive expression of IL-
8 [23–26], ii) to inactivate proteases released by the neutrophils con-
tinuously activated by bacterial products [27] and iii) to circumvent
the effect of the unbalanced production of oxidants, deriving from
both phagocytes and bronchial epithelial cells [22,28–30]. Identiﬁca-
tion of oxidants produced in the CF airway tract is of high importance,
in order to identify novel molecular targets for speciﬁc pharmacolog-
ical intervention.
2.2. Respiratory epithelial cells and neutrophils as sources of oxidants in
the CF lung
It is largely accepted that neutrophils migrating inside the CF
bronchial lumina release large amounts of reactive oxygen species
(ROS), including the superoxide anion (O2−•), hydrogen peroxide
(H2O2) and the hydroxyl free radical (OH), mainly by the activation
of the NADPH oxidase (NOX). To such exaggerated ROS production
contribute both the continuous interaction of neutrophils with bacte-
ria and bacterial degradation products and the inability to engulf bac-
teria in bioﬁlms, leading to a condition of “frustrated phagocytosis”.
Neutrophils are therefore recognized as a major source of ROS in
the airway surface liquid (ASL) of young children with CF [14,31].
However, bronchial ciliated and alveolar type II epithelial cells by
themselves are able to produce signiﬁcant amounts of ROS, through
the two isoforms of NADPH oxidase expressed in the apical membrane
of these epithelial cells, namely DUOX1 and DUOX2 [32]. A major pro-
posed function of DUOXs is to support lactoperoxidase (LPO), which is
in turn released by goblet and submucosal gland airway cells, to gen-
erate bactericidal hypothiocyanite (OSCN−) starting from thiocyanate
(SCN−) and H2O2. Thus the DUOX/LPO coupled system of the respira-
tory epithelial cells parallels the NOX/mieloperoxidase (MPO) system
of phagocytes in releasing and processing oxidants in the ASL. While
the NOX/MPO system of phagocytes is mainly activated in the
infection-induced respiratory burst, the release of ROS from epitheliais continuous and even independent of the presence of overt bacterial
infection [33]. Interestingly, it was proposed that the efﬁciency of the
DUOX/LPO defense system is dependent on the ion transport function
of the CFTR Cl− channel, which could also intervene both in the con-
ductive secretion of SCN− (for LPO function) and of HCO3− (for pH
adjustment) into the ASL [34]. However, more recent ex vivo observa-
tions, while conﬁrming a positive role of DUOX/LPO system in produc-
ing OSCN− as a general defense mechanism of the airways, do not
directly relate SCN− concentrations in ASL with CFTR function [35].
The LPO-mediated scavenging of H2O2 has suggested a role of SCN−
as physiological antioxidant of ASL [36], which may be defective in
CF. Besides this role of LPO and SCN−, an abnormal ﬂux of H2O2 in
the CF airways may also depend on other factors that are associated
with an alteredmetabolism of ROS. For instance, lowered levels of Lac-
toferrin (LF) have been described in CF secretions [37]. This iron-
chelating homologue of transferrin contained in the granules of neu-
trophils is also secreted by several mucosal tissues in biological ﬂuids
to contribute antimicrobial effects by a variety of mechanisms includ-
ing the chelating activity of iron as Fenton chemistry catalyst [38].
As regards the progression of CF lung disease, in the early phases,
before the onset of chronic bacterial colonization, epithelial DUOX
continuously releases H2O2, thus being a predominant source in
respect to the NADPH oxidase from phagocytes. The latter is mainly
active when the respiratory burst is “triggered on demand” by infec-
tious components. On the other side, in advanced phases of chronic
infection of CF lungs, neutrophil-derived ROS are predominant [32],
due to neutrophil activation as well as to the decreasing number of
H2O2-producing ciliated cells, which are reduced by extensive apo-
ptosis and tissue remodeling. A further reduction of epithelial DUOX
activity has been observed as a result of infection with P. aeruginosa
in conductive airways. P. aeruginosa-derived toxin pyocyanin in fact
inhibits DUOX-dependent H2O2 production by consuming intracellu-
lar NADPH, which represents an interesting adaptive mechanism to
downregulate innate anti-bacterial defenses [39].
2.3. Redox disturbances of CF airways: the role of GSH, NO and H2O2
Intracellular impairment of redox balance between oxidants and
anti-oxidants has been proposed to occur in CF bronchial epithelial
cells, although a signiﬁcant difference in respect to normal CFTR-
expressing cells is still controversial and debated [40]. Three major
issues have been investigated concerning the intracellular redox bal-
ance in CF bronchial cells, namely i) a defect in GSH homeostasis
[41,42], ii) an alteration of nitric oxide (NO) metabolism and iii) an
imbalance of intracellular H2O2 production.
As far as GSH is concerned, the defective CFTR channel function
has been proposed to lead to a lowered cell content of this tripeptide,
which is crucial to control the ﬂux of H2O2 in both the CF bronchial
epithelial cells and lining ﬂuids. This aspect – discussed in detail
below in this review – is associated with characteristic defects of
GSH-related enzymes and may represent a key underlying factor in
the oxidative stress of CF airways.
Altered NO concentration has been found in chronic respiratory
diseases such as bronchial asthma and chronic obstructive pulmonary
disease [43], and reduced NO concentrations have been observed in
the bronchial airways of patients affected by CF, which directly corre-
lated with worsening of lung function [44]. Thus NO concentration in
CF lung exhalate has been subsequently tested as a possible marker of
pulmonary exacerbations and/or the inﬂammatory/infective status
and its ﬂuctuations over time [45,46].
This opened the way to further analysis of the mechanisms of this
derangement, and it has been proposed that an excessive production
of asymmetric dimethylarginine, an inhibitor of endogenous NO
Synthase (NOS), could be involved in the reduced concentration
of NO in CF airways [47–49]. Possible corrective therapies, such as
the inhalation of L-arginine, have provided preliminary evidence of
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lung function in CF patients [49–51].
Although exhaled NO is decreased in CF, increased immunohisto-
chemical staining for nitrotyrosine was demonstrated in lung tissues
from CF patients [52]. Therefore, a decreased production or accelerat-
ed metabolism of NO could be present in association with an abnor-
mal reactivity of this radical and its derived species (NOx) toward
biomolecular components of the CF airways. Peroxynitrite is one of
the most relevant mediators of the biological activity of NO with
toxic properties and damaging activity on several biomolecules [53].
A third emerging issue takes into consideration the expression
of different enzymatic systems affecting the redox balance in CF bron-
chial epithelial cells. For instance, intracellular concentration of H2O2
has been found abnormally elevated in both immortalized bronchial
and primary nasal epithelial cells derived from CF patients, both
in the presence and the absence of proinﬂammatory cytokines [54].
This has been accompanied by a marked decrease of expression
of proteins regulating H2O2 levels, such as thioredoxin 1 (TRX-1),
glutathione-S-transferase pi (GST-pi), peroxyredoxin (PRDX) 6,
TRX-dependent peroxide reductase (PRDX-1), catalase and, con-
versely, a signiﬁcant increase of Mn superoxide dismutase (SOD2)
[54]. Interestingly, to link these modiﬁcations with CF speciﬁc charac-
teristics, dysfunctional CFTR channel was found associated with
reduced activity of the transcription factor Nrf-2 (nuclear factor-
erythroid 2 p45 subunit-related factor 2), which could at least in
part explain the differential expression of the enzymatic systems
resulting in the elevated intracellular steady-state concentration of
H2O2 found in CF nasal and bronchial epithelial cells [54]. In synthesis,
the ASL of CF patients during advanced stages of the lung disease con-
tains elevated concentrations of ROS, mainly derived from neutro-
phils migrated into the airway lumen, and a reduced concentration
of NO, which can strongly contribute to respiratory tissue injury
together with the proteases released by the activated neutrophils.
The homeostatic role of the GSH-related defenses appears constitu-
tively impaired by the dysfunctional CFTR, thus increasing suscepti-
bility to develop oxidative stress and lung tissue degeneration
(Fig. 1), as described in detail in the sections below.
2.4. Conductive airway epithelium as target of ROS
Oxidants can target different biomolecules to damage epithelial
cells and extracellular ﬂuids of the airways. Lipid peroxidation
and post-translational modiﬁcations of proteins on both cell mem-
branes and extracellular targets are common biomarkers of this
damage, which can occur by the direct reaction between ROS and bio-
molecules or through the formation of second-generation reactive
byproducts [9,55]. All levels of this interaction between ROS and bio-
logical components can produce toxic and bioactive intermediates.
Oxidants are known to activate secondmessengers through phospho-
lipases A2, C and D, and to induce the production of cytokines and
mucins, a series of molecular events that contribute to progressive
obstructive disease and reduction of lung function [56]. Besides the
direct oxidative damage to cellular structures of the bronchial epithe-
lial cells, the excessive concentration of oxidants in CF, both in the ASL
lining the apical membranes and inside the bronchial cells, has been
studied in respect to the regulation of the inﬂammatory response.
ROS are often considered a sort of secondmessengers in activating
the Nuclear Factor (NF)-κB, which is in turn involved in the activation
of transcription of several proinﬂammatory cytokines and chemo-
kines [57]. For instance, it has been shown that H2O2 partly controls
NF-κB activation by IL-1beta, by facilitating the activation of NIK
and subsequent phosphorylation of IKKβ [58]. In this respect, a direct
link has been proposed between the excessive production of intracel-
lular H2O2 and the elevated expression of IL-6 and IL-8, the most
abundant pro-inﬂammatory cytokine and neutrophilic chemokine
found in CF airways [54], which has been further conﬁrmed [59].Moreover, oxidants could be synergic in the induction of mucins, as
promoted by neutrophil elastase, which further impairs ASL ﬂuidity
in CF [60]. Finally, bacterial infection with P. aeruginosa strains releas-
ing the toxin pyocyanin (PCN) has been shown to reduce ion trans-
port through the CFTR channel, thus potentially counteracting the
therapeutic effects of correctors and potentiators of mutated CFTR
protein [61,62]. In summary, excessive oxidants in CF conductive air-
ways have different negative effects in the ampliﬁcation of the al-
ready excessive lung inﬂammation and secretion of mucin, together
with a direct deleterious effect on CFTR channel function.
2.5. Oxidative stress and surfactant
Oxidative stress and inﬂammation in cystic ﬁbrosis can affect sur-
factant biophysical activity thus leading to early alterations of lung
function in patients with CF [63]. Altered phospholipid-to-protein ra-
tios and phospholipid subclasses, a modiﬁed fatty acid proﬁles, and
decreased association of proteins such as SP-A with lipid components
of isolated surfactant, indicate that components of this ﬂuid are con-
siderably altered and dysfunctional in lower respiratory tract secre-
tions of CF patients [64].
Oxidative damage of surfactant may involve both lipid and protein
components. Alteration of lipid components can in turn generate
toxic lipid species with cytotoxic activity towards nearby epithelial
cells [65]. Altered protein components have been shown in cystic
ﬁbrosis [66]. Notably, surfactant protein D, which is an important in-
nate host defense molecule, becomes unable to agglutinate bacteria
when it is modiﬁed by oxidation, which facilitates pathogen coloniza-
tion in the lung [67]. In a cross-sectional analysis of CF patients with
mild lung disease, reduced surfactant activity was correlated to in-
creased neutrophilic airway inﬂammation, but not to lung function
[68]. So far, longitudinal measurements of surfactant function in CF
patients are lacking and it remains unclear how these alterations
relate to progression of airway inﬂammation as well as to the rate
of decline of pulmonary function [69].
2.6. Laboratory indices of oxidative stress in CF
Appropriate biochemical and clinical tools are of importance for
the monitoring of antioxidant therapies in CF, and a crucial aspect is
the selection of proper biomarkers and protocols to assess biological
pathways of oxidation.
Pancreatic insufﬁciency and a diminished bile acid pool cause mal-
absorption of important essential nutrients and other dietary compo-
nents in CF. Of particular signiﬁcance is the malabsorption of fat-
soluble antioxidants such as carotenoids, tocopherols and coenzyme
Q-10 (CoQ-10), which act as chain breakers in the peroxidation reac-
tions of polyunsaturated lipids. Accordingly, lipid peroxidation is one
of the main signs encountered in the CF plasma, buccal mucosal cells,
breath condensate and BALF as measured by the non-enzymatic
oxidation product of arachidonic acid 8-iso prostaglandin F2α
[5,70–73]. Elevations of this and other eicosanoids in human body
ﬂuids and tissues have been found in a diverse array of human disor-
ders, including atherosclerosis, diabetes, obesity, cigarette smoking,
neurodegenerative diseases, and many others [74]. Further, treat-
ments for some of these conditions, including antioxidant supple-
mentation, have been shown to decrease the levels of this class of
biomarkers. In CF patients, respiratory exacerbations increase plasma
levels of 8-iso-F2α [70], the levels of which in the breath condensate
negatively correlate with respiratory function data [71]. At the same
time, successful in vivo antioxidant therapy by GSH inhalation has
been shown to decreased PGE levels in BALF, in association with
changes in the number and activity of leukocyte subpopulations re-
sponsible for lung inﬂammation [73].
Oxysterols, a biomarker of cholesterol oxidation, were found to
increase in CF plasma as a further proof of the abnormal lipid
694 F. Galli et al. / Biochimica et Biophysica Acta 1822 (2012) 690–713metabolism and increased susceptibility to oxidation of lipoprotein
lipids in CF patients [7]. Importantly, an increased oxidative burden
of lung and blood lipids may produce bioactive lipid products that
further sustain CF symptoms. Besides to 8-iso-F2α and other ana-
logues with some bioactivity [74], arachidonic acid oxidation may
contribute to persistent platelet activation and pulmonary dysfunc-
tion in CF via generation of bioactive isoeicosanoids [75], which pro-
vides sufﬁcient rationale for a prevention therapy with fat soluble
antioxidants such as vitamin E. Evidence has recently accumulated
on the systemic effects of oxysterols on various tissues and organs
[76]. The role of this lipid oxidation product alone or in combination
with other factors could be further investigated in the context of
mechanisms and clinical progression of multi-organ failure of CF
patients.
The impaired pancreatic and liver functions of CF patients repre-
sent the underlying factor for a defective lipoprotein metabolism
and hypocholesterolemia, which exponentially increase the burden
of damage by cholesterol and other lipids due to reduced blood trans-
port of fat-soluble antioxidants with nascent VLDL particles. Besides
oxysterol accumulation, plasma fatty acid composition is also affected
[7], and an increased ratio between unsaturated and saturated fatty
acid species may contribute to lower cellular antioxidant defenses.
Altogether, these ﬁndings suggest that lipid oxidation biomarkers
can provide a reliable measure of systemic and lung-speciﬁc oxidative
stress in CF.
Markers of protein damage are also detectable in the airways of
children with CF and their levels are observed to parallel the extent
of neutrophilic markers and lung dysfunction [14,31,66]. Bronchoal-
veolar lavage proteins undergo halogenation of Tyr residues, a
radical-mediated process presumably depending on MPO enzyme ac-
tivity and assessed through the analysis of 3-chlorotyrosine and 3-
bromotyrosine. Thiocyanate and protein carbonyls are also useful bio-
markers to assess the inﬂammation-related injury of BALF proteins in
CF [14,31].
3. Antioxidants in CF
3.1. Glutathione and its related defense system
3.1.1. Defects in GSH homeostasis
Other studies have pointed to alterations in the levels of extracel-
lular antioxidants in respiratory tract lining ﬂuids [3]. In particular,
the analyses of broncheoalveolar lavages (BAL) have revealed the
presence of decreased levels of GSH in the alveolar epithelial lining
ﬂuid of CF patients. The normal level of extracellular GSH in the
lung is 140 times that present in blood plasma, and the lung is a net
importer of circulating GSH [77]. As a result, GSH concentration in
ELF is close to 400 μM, whereas signiﬁcantly reduced GSH levels are
present in adult CF patients [41]. Low levels of GSH have been ob-
served in plasma and blood neutrophils [41,78] suggesting systemic
GSH dyshomeostasis in CF. Moreover, some studies have shown that
at the cellular level, the CFTR mutation causes mitochondrial deple-
tion of GSH [79,80]. The consequences of this defect are still difﬁcult
to be understood due to our poor knowledge about the exact func-
tions of GSH in the lung, but there are reasons to believe that the
decrease of GSH in the ASL contributes to lung infection and inﬂam-
mation [42,81]. At the same time, it must be underlined that a recent
study has shown that the GSH content in sputum samples is higher in
CF patients than in healthy people, indicating that GSH deﬁciency in
CF is restricted to the lower respiratory tract [82]. Several hypotheses
have been proposed to explain such a local increase in GSH, including
the possibility that it may derive from apoptotic neutrophils. The re-
lease of high levels of GSH may be part of a compensatory mechanism
aimed at controlling disulﬁde bonds-mediated aggregation of mucins.
Secretions of the upper respiratory tract contain abundant levels of
these glycosylated and cysteine-rich proteins, likely playing a role inthe airway antioxidant defense. Indeed, these proteins are potent in
vitro ROS scavenges [83] and their synthesis is upregulated upon ox-
idative stress via epidermal growth factor receptor (EGFR) transacti-
vation [84].
GSH, a major component of cellular antioxidant defenses, exerts im-
portant functions related to its electron-donating capacity, including
protection from the damaging effects of ROS and regulation of a pletho-
ra of cellular events, such as gene expression, proliferation and differen-
tiation, apoptosis and immune response [85]. GSH is synthesized by two
sequential ATP-dependent reactions catalyzed by γ-glutamylcysteine
synthetase (recently, renamed glutamate-cysteine ligase) andGSH syn-
thetase. The reaction catalyzed by γ-glutamylcysteine synthetase, i.e.
the formation of γ-glutamylcysteine from glutamate and cysteine, is
the rate-limiting step in GSH synthesis and is feedback regulated by
GSH itself. In fact, this enzyme represents an interesting case of redox-
regulation of catalytic activity that is mediated by the reversible forma-
tion of disulﬁde bonds [86]. Oxidizing conditions causing GSH depletion
promote the formation of a disulﬁde bondbetween the catalytic and the
regulatory subunits of the enzyme, leading to a conformational change
which favors the binding of glutamate. In contrast, physiological levels
of GSH reduce this disulﬁde bond, thus explaining GSH feedback
inhibition.
Either in intracellular or extracellular compartments, GSH is pre-
dominantly found in the reduced form, although small amounts of
the oxidized disulﬁde forms (GSSG or GSSR, where a GSH molecule
is linked to a free or a protein thiol) can always be detected. GSSG is
produced by the catalysis of glutathione peroxidase, during the
detoxiﬁcation from hydrogen peroxide and other peroxides, or by
the direct reactions of GSH with electrophilic compounds, such as
radical species. Despite the bulk of GSH synthesis occurring in the
cytoplasm, GSH is distributed in intracellular organelles, including
the endoplasmic reticulum, mitochondria and nucleus. Under physio-
logical conditions, the GSH to GSSG ratio in these compartments is
high, frequently >100/1, but this may change under conditions of ox-
idative stress [87]. A major exception is represented by the endoplas-
mic reticulum, where GSSG is present at much higher levels to favor
disulﬁde bond formation [88]. Interestingly, the compartmentaliza-
tion of GSH in separate pools within organelles allows localized alter-
ations in the balance between GSH and GSSG that may have
considerable functional and pathological signiﬁcance [89]. This
could be particularly important in CF, in view of the above mentioned
studies showing that cultured CF cells have an apparent normal GSH/
GSSG content, but are characterized by a marked decrease in mito-
chondrial GSH in association to elevated mitochondrial ROS [79,80].
Different roles of high levels of GSH in the ELF may be hypothe-
sized, including: a) preventing inﬂammation and tissue damage by
scavenging the ROS spontaneously generated in this highly oxidizing
environment, actively produced by neutrophils during inﬂammation
or originating from lipid peroxidation, b) regulating the redox status
of membrane proteins involved in the transduction of signals leading
to changes in the expression of genes involved in the immune re-
sponse, c) controlling mucus viscosity by breaking disulphide bonds,
d) modulating the response to bacterial infections. This last possibili-
ty is suggested by the observation that GSH signiﬁcantly increases
in the ASL of wild type mice following P. aeruginosa infection, where-
as this response is not observed in CFTR mutant mice [90]. Interest-
ingly, some authors have suggested the ability of GSH to control P.
aeruginosa growth and resistance to antibiotics, although these stud-
ies should be considered with some cautions due to the likely use of
unbuffered GSH [91].
Although the decreased levels of GSH in ELF could be due to in-
creased consumption during inﬂammation-related oxidative stress
[41,92], GSH deﬁciency in CF ELF likely derives from CFTR channel
dysfunction. In fact, comparable alterations in GSH extracellular con-
tent characterize the lung of CFTR knockout mice [93], indicating that
this defect is correlated to mutations in CFTR.
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B6.129P2-Cftrtm1Unc) and wild-type mice were compared for GSH
content and the activities of glutathione-related enzymes [93]. In
the ELF, the concentration of GSH was signiﬁcantly decreased in the
Cftr KO mice compared to WT, whereas tissue concentrations of
GSH were similar [92]. In the Cftr KO lung, the activities of glutathione
reductase and glutathione peroxidase were increased, whereas the
activity of γ-glutamyltransferase was unchanged. Two indicators of
oxidative stress, thiobarbituric acid reactive substances (TBARS) and
8-hydroxy-2-deoxyguanosine (8-OHdG), were also increased in the
Cftr KO lung tissue [90]. These data support the hypothesis that a mu-
tation in the CFTR gene can affect the antioxidant defenses in the lung
and may contribute to the exaggerated inﬂammatory response ob-
served in CF. Thereby, CFTR could be considered as an important
actor of ELF antioxidant homeostasis and thus an intrinsic cause of
oxidative imbalance in CF airways of human patients as well as Cftr
KO mice.
Moreover, CFTR belongs to the MRP/ABC family of proteins which
includes several GSH transporters and some in vitro studies have in-
dicated that CFTR may mediate GSH export across membranes
[2,3,94]. Despite these evidences, there is still debate about the phys-
iological implication of CFTR in GSH transport outside the cells as
other studies have raised the possibility that CFTR may not actually
conduct GSH, but regulate its transport indirectly through chloride
transport [85].3.1.2. In vitro studies suggesting a protective role of GSH in CF model
systems
Possible protective roles of extracellular GSH in the CF lung have
been long proposed and recent in vitro studies have provided further
and more robust support to this clue. For example, it has been sug-
gested that GSH may control the levels of chlorinated compounds
formed by the activity of myeloperoxidase, a neutrophil-released
protein abundantly present in CF patients secretions [95,96] and pre-
vent NK-κB activation [96]. Other studies have suggested that CFTR
mutant cells produce higher levels of proinﬂammatory cytokines in
response to P. aeruginosa diffusible material with respect to wild
type cells, through a mechanism involving the activation of NADPH
oxidase. This effect may be signiﬁcantly reversed by the addition of
extracellular GSH [97].
GSH could also play an important role in protecting the lung epi-
thelia from the toxic effects of pyocyanin (PCN), a redox-active exo-
toxin released by P. aeruginosa which is supposed to cause a variety
of deleterious effects on the airway physiology [98]. PCN levels as
high as 130 μM have been measured in pulmonary secretions of pa-
tients with CF and individuals with chronic bronchiectasis [99]. At
concentrations within the range measured in the sputum from CF pa-
tients, PCN induces a drastic reduction of intracellular GSH [100,101],
promotes death of cultured cells [100] and causes pathophysiological
alterations in the lung of wild type mice that are consistent with the
changes observed in CF patients [102]. PCN toxicity likely derives
from its ability to accept electrons from cellular reductants and then
react with oxygen to generate superoxide and other ROS [103]. There-
fore, GSH deﬁciency is explained either by the reaction of GSH with
such oxidants or through the direct reaction of PCN with GSH that
leads to the formation of a PCN radical [103]. However, the electron
transfer from GSH to PCN does not occur at neutral pH and recent ob-
servations suggest that extracellular GSH provides signiﬁcant protec-
tion against the toxic effects of PCN [104]. Moreover, GSH can react
with PCN to form a stable adduct which is likely redox inactive
[105]. Although the relationships between extracellular GSH and
PCN are still contradictory, it is worth mentioning that extracellular
GSH increases to millimolar levels in the ELF of wild type mice
infected with P. aeruginosa, indicating that GSH may be useful to re-
sist to bacterial colonization [90]. Interestingly, in vitro studies haverevealed that extracellular GSH inhibits the ability of Burkholderia
cenocepacia to enter epithelial respiratory cells and reduces bacterial
induced expression of proinﬂammatory cytokines (D'Orazio, Pacello
and Battistoni 2011, unpublished results).3.2. GSH-based antioxidant therapies
3.2.1. Preclinical studies in animal models of CF
Mice genetically modiﬁed for the Cftr gene, along with acute and
chronic infection induced by CF-related pathogens, are a key asset in
CF research. Although much has been learned through these CF
mousemodels, limitations in the ability of this species to recapitulate
spontaneous lung disease and several other organ abnormalities
seen in CF humans, including few airway mucous glands, have creat-
ed a need for additional species on which to study CF [106]. To this
end, pig and ferret CF models have been generated and are currently
being characterized [107,108]. These new larger animal models have
phenotypes that appear to closely resemble human CF disease seen
in newborns, and efforts to characterize their adult phenotypes are
ongoing. However, mice have been the dominant species by which
to study CF disease processes in vivo and develop therapies for the
past two decades including GSH-based antioxidant treatment.
Despite limitations and signiﬁcant species differences between
mice and humans, these models proved to be useful tools to mimic
the initial and progressive bronchopulmonary infection typical of CF
patients [109]. In particular, the model of chronic infection, which
challenge bacterial cells with agar as an immobilizing agent, has
been extensively characterized, and induce the long-term persistence
of the bacterial infection and lung pathology, including airway inﬂam-
mation [110,111]. Lung pathology associatedwith chronic experimen-
tal infection resembled some aspects of the advanced chronic
pulmonary disease at autopsy in CF patients [112–114]. Both naturally
occurring and experimental infections frequently manifest broncho-
pneumonia, bronchiectasis, mucus plugging, epithelial metaplasia,
ﬁbrosis, and alveolar exudates with inﬂammatory cells. Lymphoid
hyperplasia, which was prominent in the infected animals, was also
a common ﬁnding in the lungs of CF patients. In addition, signiﬁcant
differences with regard to weight loss, BAL neutrophil counts and
cytokine concentrations have been detected. Infected mice had a
rapid though transient rise in absolute neutrophil counts, TNF-α, IL-
1β, IL-6, MIP-2, and KC in bronchoalveolar lavage (BAL) [110,115]. In
addition, the generation of CF mice has allowed the possibility of in
vivo testing of novel therapies before entering in clinical trial. These
include the pre-clinical evaluation of antibiotics and biotechnological
drugs, as well as of natural and synthetic anti-inﬂammatory agents
that reduce the excessive recruitment of neutrophils and the progres-
sive damage of the respiratory tissue by the unbalanced production of
oxidants.
Regarding antioxidants, GSH and its pro-drug N-acetylcysteine
(NAC) remain the so far most investigated antioxidant agents in CF
and several strategies have been proposed to improve systemic and
lung GSH status of CF patients based on pre-clinical studies, including
the administration of nebulized GSH by inhalation or the oral supple-
mentation of GSH or NAC. Oral GSH administration can raise serum
and lung tissue GSH levels in rodents [116,117]. In these studies
GSH was administered to animals dissolved in saline or PBS. The
pharmacokinetic proﬁle of an oral bolus dose of GSH (300 mg/kg)
was determined in mice in other studies [118]. Plasma, ELF, BAL
cells, and lung tissue were analyzed for GSH content. There was a
rapid elevation in the GSH levels that peaked at 30 min in the plasma
and 60 min in the lung, ELF, and BAL cells after oral GSH dosing. Oral
GSH treatment produced a selective increase in the reduced and ac-
tive form of GSH in all lung compartments examined. Oral GSSG treat-
ment (300 mg/kg) resulted in a smaller increase of GSH levels. To
evaluate the role of CFTR in this process, Cftr KO mice and gut-
Table 1
Intervention trials on antioxidant therapy in CF patients found at ClinicalTrials.gov databasea.
Rank Title PI Location Recruitment Interventions Age groups Phases;
number
enrolled
Study designsb Outcome measures Start and
completion date
NCT ID
1 Efﬁcacy and safety study
of inhaled GSH in CF
patients
Griese
M.
Germany Completed Drug:
• reduced GSH sodium salt
C|A|S II
138
1. R|E
2. Safety/eff
3. PA
4. DB (Sub, Inv)
5. Treatment
• Differences between inhaled GSH
and inhaled normal saline with
respect to the area under the curve
of FEV1% predicted within the period
from baseline to week 24;
• Treatment changes with respect to
the variables:spirometry, peak ﬂow,
quality-of-life, weight/height,
percentage of neutrophils/other
cell types (induced sputum), induced
sputum levels of GSH/inﬂammatory
mediators, pulmonary exacerbation
Jul-07
May-10
00506688
• 0.9% saline (control)
2 A phase I study of inhaled
sodium pyruvate for the
treatment of CF
Billings
M.C.E.
United States Terminated Drug:
• Inhaled sodium pyruvate
A|S I
70
1. R|E
2. Safety/eff
3. PA
4. DB
5. Treatment
• Assessment of safety of inhaled sodium
pyruvate in Subs with CF. Subs will be
evaluated for the presence of symptoms
and safety laboratory measurements.
• Determination of improvement in
lungs of CF Subs as determined by
measurement of FEV1 and measurement
of inﬂammatory markers in
induced sputum.
Feb-06
n.a.
00332215
3 Inhaled GSH versus
placebo in CF
Marsico
S.
Italy Recruiting Drug:
• Inhaled reduced GSH
• Physiological solution
C|A III
150
1. R|E
2. Eff
3. PA
4. SB (Sub)
5. Treatment
• FEV1%
• Small airway function; exercise capacity;
BMI; dyspnoea; cough; quality of life;
pulmonary exacerbations; markers of
oxidative stress (H2O2)in serum and in
EBC; epithelial inﬂammatory markers
on BNEC
Jun-10
Dec-12
01450267
4 Safety and efﬁcacy of
an antioxidant-rich
multivitamin
supplement in CF
Sagel
S.D.
United States Completed Dietary supplement:
• AquADEKs
C|A II–II
17
1. NR|E
2. Safety/eff
3. SGA
4. OL
5. Treatment
• Plasma levels of β-carotene
• Plasma levels of coenzyme Q-10,
retinol (Vitamin A), 25-hydroxy vitamin
D, α- and γ-tocopherols (Vitamin E),
PIVKA-II
Aug-07
Nov-09
01018303
5 Efﬁcacy and safety of
epigallocatechin gallate
(EGCG)/tocotrienol in
18 patients with splicing-
mutation-mediated CF
Kerem
E.
Israel Not yet
recruiting
Dietary supplement:
• EGCG
• Tocotrienol
• EGCG+tocotrienol
A|S n.a.
18
2. Safety/eff
3. CA
4. OL
5. Treatment
• Changes in nasal chloride secretion as
assessed by TEPD, with assessment of
mean changes in TEPD by drug compared
to baseline and the proportion of patients
with a chloride secretion response by
drug compared to baseline
• Pulmonary function testing: FEV1,
FVC, MEF25-75
Sep-09
Jun-11
00889434
6 The effect of inhaled
NAC compared to
normal saline on
sputum rheology and
lung function
Van
Daele S.
Belgium Terminated Drug:
• Acetyl-Cys
• Normal saline
C|A IV
19
1. NR|E
2. Eff
3. CA
4. OL
5. Treatment
• Changes in visco-elasticity and
lung function
Jan-10
Dec-10
00996424
696
F.G
alliet
al./
Biochim
ica
et
Biophysica
A
cta
1822
(2012)
690
–713
7 Safety of orally
administered
curcuminoids in adult
subjects with CF
Goss C. United States Completed Drug:
• Standardized turmeric
root extract
A I
11
1. NR|E
2. Safety/eff
3. SGA
4. OL
5. Treatment
• Safety and tolerability of 14 days of
treatment with orally administered
curcuminoids as assessed by adverse
events, laboratory parameters, and
spirometry.
• Pharmacokinetics of repeated doses
of orally administered curcuminoids;
change in NPD measurements.
change in sweat chloride measurements.
Apr-05
Jan-06
00219882
8 Nasal potential studies
utilizing CF transmembrane
regulator (CFTR) modulators
Rowe S. United States Recruiting Other: quercetin C|A II
46
2. Eff
3. SGA
4. OL
5. BS
• NPD(NPD) Biomarker
• Residual CFTR activity
Mar-10
Nov-11
01348204
9 Safety and tolerability of
inhaled nitric oxide in
patients with CF
Sagel S. United States Completed Drug:
• Nitric oxide for inhalation
• Nitrogen
C|A|S II–II
18
1. R|E
2. Saf
3. PA
4. DB (Sub, Care, Inv, OA)
5. Treatment
• Safety and tolerability of drug,
assessed by change in methemoglobin
levels, oxygen
saturation, FEV1
• Assess the difference in sputum
bacterial density before and after
NO inhalation, and the difference
in lower airway inﬂammatory
measures before and after NO inhalation
Jul-04
Dec-08
00570349
10 NAC Phase IIB: a multi-
center, phase IIB,
randomized, placebo-
controlled, DB study of
the effects of NAC on
redox changes and lung
inﬂammation in CF patients
Conrad
C.
United States Completed Drug:
• NAC
C|A|S II
80
1. R|E
2. Eff
3. SGA
4. DB (Sub, Care, Inv, OA)
5. Treatment
• Change in the logarithm of the level
of human neutrophil elastase
(HNE) activity measured in sputum
• Change in concentration of IL-8
measured in sputum and plasma;
concentration of GSH measured in
whole blood; the neutrophil count
measured in sputum
Nov-08
Feb-11
00809094
11 Glutamine supplementation
in CF
n.a. United States Not yet
recruiting
Dietary supplement:
• Glutamine
• L-alanine
A|S II
40
1. R
3. PA
4. DB (Sub, Care, Inv, OA)
5. Prev
• Percent increase in plasma glutamine
and GSH redox levels measured at
weeks 0, 4, 8, and 12.
Feb-10
Feb-11
01051999
12 Effect of sulforaphane in
broccoli sprouts on
Nrf2 activation
Chmiel
J.F.
United States Active, not
recruiting
Dietary supplement:
• Broccoli sprouts
A n.a.
15
3. SGA
4. OL
5. BS
• Nrf2 activation in NEC
• Measures of lipid peroxidation in NEC;
GSH from blood lymphocytes;
oxidative stress in urine;
neutrophil migration into the
gingival crevices
Apr-11
Sep-11
01315665
Abbreviations:
A=adult; BC=breath condensate; BNEC=brushed nasal epithelial cells; BS=basic science; C=child; CA=crossover assignment ; Care=caregiver; CF=cystic ﬁbrosis; DB=double blind; EBC=exhaled breath condensate; Eff=efﬁcacy
study; FEV1=forced expiratory volume in 1 s; FVC=forced vital capacity; GSH=glutathione; Inv=investigator; MEF25–75=maximal expiratory ﬂow 25–75; n.a.=not available; NAC=N-acetylcysteine; NEC=nasal epithelial cells;
NLF=nasal lavage ﬂuid; NPD=nasal potential difference; NR|E=non-randomized|endpoint; OA=outcomes assessor; OL=open label; PA=parallel assignment; PI=principal investigator; Prev=prevention; R|E=randomized|
endpoint; S=senior; Saf=safety study; SB=single blind; SGA=single group assignment; Sub=subject.
a Search was done matching the terms “antioxidant therapy” or “Glutathione” with “Cystic Fibrosis”.
b 1. Allocation; 2. Classiﬁcation; 3. Intervention model; 4. Masking; 5. Primary purpose.
697
F.G
alliet
al./
Biochim
ica
et
Biophysica
A
cta
1822
(2012)
690
–713
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GSH (300 mg/kg) and compared with WT mice for changes in GSH
levels in plasma, lung, ELF, and BAL cells. There was a twofold in-
crease in plasma, a twofold increase in lung, a ﬁvefold increase in
ELF, and a threefold increase in BAL cell GSH levels at 60 min in WT
mice; however, GSH levels only increased by 40% in the plasma, 60%
in the lung, 50% in the ELF, and twofold in the BAL cells within the
gut-corrected Cftr KO-Tg mice. No change in GSH levels was observed
in the uncorrected Cftr KO mice. These studies suggest that oral GSH
administration can increase plasma and lung compartment GSH
levels in WT mice and to a lesser extent in gut-corrected Cftr KO-Tg
animals. It also suggests that oral GSH treatment can boost BAL cell
GSH levels. However, since this study failed to show signiﬁcant in-
creases in serum and lung compartment GSH levels in uncorrected
Cftr KO mice, it is questionable whether oral GSH administration to
CF patients with intestinal malabsorption would beneﬁt from this
therapy. It was also shown that GSH is rapidly distributed to the
serum and lung compartments. Kariya et al. [118] speculate that
other transporter(s) besides CFTR are responsible of the transport of
GSH and probably of other dietary molecules to the lung, which
may be responsible for dietary deﬁciencies observed in various lung
diseases.
Another strategy is represented by the oral supplementation of
high doses of NAC, a well known cysteine donor for the synthesis of
glutathione. NAC is considered a safe molecule, which has been
used successfully to treat GSH deﬁciency in a wide range of diseases
[119]. As CF mice display defects in GSH export in the ELF comparable
to those of patients, they could provide a useful tool to assess the ef-
fects of NAC administration on the GSH status. However, only limited
studies exploring the effects of NAC on CF animal models have been
so far carried out. The effects of NAC have been tested on mucus accu-
mulation, bacterial load, transit, and inﬂammation in the CF mouse
small intestine showing that NAC may reduce intestinal mucus accu-
mulation bacterial overgrowth in the gut [120].
Moreover, NAC has been reported to restore the accumulation
of unwanted/misfolded proteins in aggregates that are associated with
the CF airway phenotype as a cause of lung inﬂammation [121]. The
mechanism of this NAC-derived effect seems to involve the restoration
of beclin 1 expression and activity in the autophagy pathway of the
endoplasmic reticulum that was investigated in vivo using Scnn1b-
transgenic and Cftr(F508del) homozygous mice. The restoration of
this pathway also produced a rescued trafﬁcking of CFTR (F508del) to
the cell surface of CF cells obtained from human CF nasal biopsies.
Given the defective GSH metabolism of CF reviewed in the previ-
ous sections and in [122], and the reduced response to GSH therapy
in CF mice [93], some Authors have investigated the inﬂuence of bac-
terial infections on lung oxidative stress. The effects of P. aeruginosa
infection on ELF and lung tissue antioxidants and the oxidation of
DNA and lipids were investigated in mice challenged with bacterial
cells [90]. CFTR-KO (B6.129P2-Cftrtm1Unc) and WT mice were chal-
lenged intratracheally with a clinical isolate of mucoid P. aeruginosa
embedded in agar beads and on the third day of infection BALF and
lung tissue were obtained and analyzed for cytokines, antioxidants
and enzyme activities [90]. P. aeruginosa lung infection increased
levels of inﬂammatory cytokines and neutrophils in the ELF. This cor-
responded with a marked increase in GSH and in urate levels in the
ELF of P. aeruginosa-infected WT mice. A twofold increase in urate
levels was also observed among lung tissue antioxidants of P.
aeruginosa-infected WT mice. There were no changes in markers of
lung oxidative stress associated with the P. aeruginosa lung infection.
In contrast to WT mice, the CFTR-KO mice lacked a signiﬁcant in-
crease in ELF GSH when challenged with P. aeruginosa, and this corre-
lated with a decrease in the ratio of reduced to oxidized GSH in the
ELF, a marker of oxidative stress. These data would suggest that the
lung adapts to infectious agents with elevated ELF GSH and urate.
Therefore, individuals with lung diseases associated with alteredantioxidant transport, such as CF, might lack the ability to adapt to
the infection which may lead to a more severe inﬂammatory
response.
3.2.2. Clinical trials on GSH
The discovery of the defect in GSH export has suggested that ther-
apies able to restore or increase GSH levels in the ASL could counteract
the inﬂammation and oxidative stress conditions typical of CF pa-
tients. In an attempt to strengthen extracellular defenses against
ROS, some pilot studies have analyzed the effect of GSH inhalation or
that of oral GSH prodrug N-acetylcysteine (NAC). All these treatments
were well tolerated by the CF patients and most authors were able to
measure increased ELF concentrations of GSH in association with
some positive clinical outcomes [40,41,73,78,96,122–128]. Although
potentially promising, these ﬁndings need stronger clinical evidence
in that the majority of these were obtained on very limited number
of patients investigated in non-randomized controlled trials. This is
highlighted in a recently published meta-analysis [129] that provides
also a thoroughly analysis of the literature on this aspect of the antiox-
idant and anti-inﬂammatory therapy of CF. Among the American CF
foundation sponsored trials two phase II trials on inhaled GSH and
oral NAC are in progress in US and Germany (ClinicalTrials.gov, Iden-
tiﬁer: NCT00506688 and NCT00809094, respectively; Table 1), and
safety and tolerability of aerosolized glutathione is also matter of
investigation by another (not registered) US trial (more information
on this can be found in [130]). Nevertheless, the diffusion among CF
patients of NAC preparations for inhalation (Mucomyst®) has in-
creased in recent years.
γ-Glutamylcysteine ethyl ester (GCEE) is another potentially inter-
esting GSH pro-drug, which has proved some efﬁcacy in the ameliora-
tion of oxidative stress e.g. in experimental myocardial infarction
[131] and central nervous system conditions (see e.g. [132]). However,
GCEE has not been investigated in CF yet.
3.3. Limits and potential problems associated to thiol-based therapies
Although the above cited clinical trials may be considered promis-
ing attempts to improve the antioxidant levels in the ELF, the actual
capacity of these treatments to produce positive clinical effects must
be considered with caution. For example, indices of oxidative damage
were found to be unaffected by aerosolized GSH treatment [122].
Some in vitro studies have suggested that the reaction of GSH with
PCN could produce hydrogen peroxide, with potential exacerbation
of oxidative damage [101]. The exact mechanisms of PCN toxicity
and the reaction of this toxin with GSH must be better understood
in order to evaluate the safety of GSH administration to patients col-
onized by P. aeruginosa.
Inhalation of GSH ensures its direct delivery in the airways, but
since GSH can rapidly convert to its oxidized form GSSG, frequent
GSH inhalations are required to maintain a high GSH/GSSG. As a con-
sequence of this limit, four separate inhalations have been used in
the study carried out by Bishop et al. [123]. Unless justiﬁed by clear
clinical improvements, these repeated treatments may represent a
burden for patients already undergoing complex therapies. Moreover,
repeated inhalations of GSH increase the levels of GSSG in ELF
[133,134]. In the absence of effective homeostatic mechanisms ensur-
ing the fast recycling of GSSG to GSH, this might produce unwanted
effects and even the exacerbation of CF symptoms being GSSG re-
sponsible of the S-glutathiolation and functional inhibition of CFTR
[124].
In principle, the oral administration of GSH could be considered a
safe strategy to prevent GSSG accumulation, but this strategy is likely
not feasible due to the substantial inability of this water-soluble mol-
ecule to cross biological membranes. Moreover, a study carried out in
mice has established that GSH absorption in the gastrointestinal tract,
if any, is mediated by CFTR itself, thus excluding the possibility to
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supplementation of the antioxidant [127]. The limited absorption of
GSH could be overcome by GSH-esters, as in vitro studies have
shown that this form of GSH may be speciﬁcally useful to rescue mi-
tochondrial defects in cystic ﬁbrosis models [80]. Safety of these GSH
derivatives in humans has been poorly investigated.
Two independent studies have shown that the treatment of CF pa-
tients with high doses of NAC increases extracellular GSH in sputum
[78,125], but contrasting results have been reported concerning the
effects of NAC on the concentrations of blood GSH and on the levels
of IL-8 and other markers of inﬂammation. NAC treatments may be
useful to modulate the GSH content in cells but it should be reminded
that an enhanced cysteine supply cannot lead to an increase of GSH
above physiological levels due to the feedback inhibition mechanism
of γ-glutamylcysteine synthetase, described in the Section 3.1.1.
3.3.1. Gamma-glutamyltransferase and GSH therapy
So far none of the studies mentioned above has taken into account
the fact that GSH is degraded by GGT enzyme activity. GGT concentra-
tions are known to increase several fold in ELF of CF patients, even if
the mechanisms for this effect were not determined [135], and this
phenomenon parallels the above described decrease of GSH levels in
ELF. Preliminary data suggest that a major source of increased ELF
GGT is represented by activated neutrophils accumulating in diseased
airways (Corti and Pompella, 2011, unpublished observation). Re-
gardless of its origin, it is likely that increased GGT in ELF would de-
grade locally administered GSH to variable extents, which could
contribute to the so far inconclusive results of therapies based on
aerosolized GSH. Besides its role in GSH catabolism, GGT has been
shown to mediate protein S-thiolation [136], suggesting that GSH ad-
ministration in the presence of active GGT enzyme might alter CFTR
glutathiolation status and function in a potentially unfavorable way.
On the other hand, a potential role of GGT in favoring bronchial up-
take of antioxidant vitamin C has also been suggested [137].
These controversial ﬁndings may add further issues to the ques-
tion of whether the therapy of lung oxidative stress by aerosolized
GSH could be safe in all the CF patients regardless of speciﬁc strate-
gies that would ascertain the extent of lung inﬂammation. These
strategies should include the assay of GGT levels in ELF. In principle,
once an adverse role of ELF GGT in GSH therapies will be conﬁrmed,
the association of GGT inhibitors in the GSH formulations for inhala-
tion could represent a promising pharmacological strategy.
3.4. Malnutrition as a possible cause of defective thiol-dependent
antioxidant protection
Successful nutritional interventions strongly impact on the clinical
outcome of CF patients [138–140]. Malnutrition by pancreatic insufﬁ-
ciency and other CF-related factors inﬂuence the susceptibility to de-
velop recurrent infections and severe inﬂammatory lesions of the
lung tissue. If the onset of a defective (sub-optimal) antioxidant sta-
tus may represent an underlying component in the clinical effects of
malnutrition remains a matter of investigation. Clinicians have to
pay particular care to avoid these disturbances and successful proto-
cols of nutritional intervention in CF have been developed, which
are essentially aimed to avoid the onset of protein-energy malnutri-
tion (PEM) [141]. Despite this, the risk of developing such an unto-
ward complication in CF infants and children remains high as
suggested by the prevalence data registered in some areas. Actually,
a prevalence of PEM between 5 and 14% in Moldavian infants was re-
cently reported [142] and PEM is associated with poor outcome and
particularly with the risk of developing edema and anemia.
Besides lowered intake and absorption of micronutrient antioxi-
dants discussed in the other sections, malabsorption of dietary protein
and excess fecal amino acid losses result in hypoproteinemia/hypoalbu-
minemia as key biochemical signs of PEM. Hypoalbuminemia isconsidered to be linked with a cause–effect relationship with oxidative
stress and is proposed to inﬂuence morbidity and mortality in condi-
tions associated with chronic inﬂammation and severe oxidative stress
[143,144]. The human serum albumin (HAS) molecule contains only a
reactive thiol group, e.g. the Cys 34, the importance of which as an anti-
oxidant defense system in blood and for the entire organism is well
documented [145]. This is the second main thiol (and the main protein
thiol) in the circulation (approx. 2 mmol in the adult organism, assum-
ing 5 l of total blood volume, anHt of 40% and [HAS] of 45 g/l of plasma),
being the RBCGSH theﬁrst thiol in blood (near to 5 mmol, assuming the
same parameters of above and an average concentration of GSH in
packed RBC of 2.5 mM) [146,147]. The antioxidant role of HSA is not
only a consequence of the relative abundance of its Cys thiol. A speciﬁc
capability of acting as a sacriﬁcial target for a series of electrophils and
most biologically relevant ROS, i.e. hydrogen peroxide and peroxyni-
trite has been demonstrated in a series of studies [145,148,149]. Li-
gand binding activity can contribute to promote antioxidant effects
by the HSA molecule [145]. Transitions metals, particularly copper
and also iron in the case of iron-overload diseases, bind to HSA. In
this way, these are less available to promote the Fenton chemistry
and hydroxyl radicals eventually released from this oxidative reaction
are mostly directed to the HAS protein sparing more important tar-
gets. A free radical-trapping activity of HSA has been also demonstrated
and this was proposed to be directed toward both hydrophilic and fat-
soluble species. This activity may result from the interaction with
other antioxidants such as α-tocopherol [150] and may inﬂuence the
antioxidant activity of food-derived phenolic antioxidants [151].
However, Cys 34 is considered the main contributor to the antiox-
idant function of HAS, which plays its role in the antioxidant homeo-
stasis of blood thanks to a complex series of interactions with the
metabolism and antioxidant function of the pool of free thiols in plas-
ma and in the circulating RBC, with the latter playing a signiﬁcant
contribution to the extracellular pool of GSH [146] and to the dynam-
ics of inter-organ GSHmetabolism in cooperation with liver and other
tissues [147]. Immuno-inﬂammatory cells and the lung tissue are
among the main terminals of this metabolism. The RBC contain the
entire machinery to synthesize GSH, to restore its redox (by enzymat-
ic reduction of the oxidized form), and to use this as cofactor of Se-
GPx and GSH-S-transferase enzymatic activities that are responsible
of the detoxiﬁcation of hydroperoxides and alkylating agents that
may form in or enter the RBC cytosol [147]. In this sense, the RBC rep-
resents a circulating reservoir of GSH that, in addition to maintaining
the redox and respiratory function of Hb, participates to systemic pro-
tection of xenobiotics of endogenous and exogenous origin. In consid-
eration of these aspects, the combination of hypoalbuminemia and
anemia may exponentially increase the risk of developing oxidative
stress in CF patients as it is supposed to occur in other oxidative stress
conditions such as chronic kidney disease [55,143,152]. Additional
clinical investigation should verify the hypothesis that hypoalbumi-
nemia together with a defective uptake and metabolism of sulfur-
containing amino acids and CF-speciﬁc defects of the GSH metabo-
lism, may represent a causal risk factor for an impaired antioxidant
defense and systemic oxidative stress in CF patients.
3.5. Fat-soluble antioxidants
Pancreatic insufﬁciency and a diminished bile acid pool cause mal-
absorption of important essential nutrients and other dietary compo-
nents in CF. Of particular signiﬁcance is the malabsorption of fat-
soluble antioxidants such as tocopherols, carotenoids and coenzyme
Q-10 (Co-Q10), and that of essential fatty acids (EFA).
3.5.1. Vitamin E
Vitamin E therapy in CF has been proposed in several decades of
research as a useful approach to overcome both the lower absorption
of this fat-soluble micronutrient and the increased antioxidant
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stance the recommendations by the Cystic Fibrosis Foundation Con-
sensus Conference on nutrition [153]).
The ﬁrst report of a vitamin E deﬁciency in CF appeared in literature
in 1951 by Filer et al. [154]. In this study, the absorption of the main
form of this vitamin, e.g. α-tocopherol, and its ester derivatives was in-
vestigated in several subsets of infants and children. Thanks to a simple
bioavailability (or tolerance) test, these authors observed that “in-
fants… diagnosed as ﬁbrocystic disease of the pancreas, diarrhea and
cirrhosis were characterized by a poor response to the test, i.e., the tol-
erance curve was low”. However, abnormalities were also observed in
other subgroups of infants with a variety of disorders not associated
with fat or fat-soluble vitamin intolerance, such as sprue, celiac syn-
drome and lupus erythematosus, which suggests the general observa-
tion that malnutrition and inﬂammatory and degenerative diseases of
the GI tract, may lead to absorb tocopherols poorly. At the same time,
these authors reported that “Metabolic disorders with associated hy-
percholesterolemia were observed to give abnormally high values for
the area under the curve” and that patients responding poorly to to-
copherol absorption test did also in vitamin A absorption tests.
The ﬁnding of lowered (lipid uncorrected) levels of vitamin E was
conﬁrmed in other studies in which this relative deﬁciency was found
to occur irrespective of pancreatic comorbidity and in association
with lowered levels of other liposoluble vitamins such as vitamin A
and D [155] regardless of their different liver metabolism and tissue
delivery mechanisms [156,157].
Plasma, buccal mucosal cells (BMCs), and breath condensate α-
tocopherol decreased signiﬁcantly with age in association with a de-
creased respiratory function [5]. This was accompanied by lowered
levels of other antioxidants such as vitamin C, and increased oxidative
stress markers of different origin such as protein carbonyls, thiobarbi-
turic acid-reactive substances, and F2-IsoPs.
Clinical symptoms of vitamin E deﬁciency in CF have not been
conclusively investigated. Dolan et al. [158] described that anemia
of CF patients is related to vitamin E deﬁciency and increased
peroxide-induced hemolysis of RBC. Other authors, however, ob-
served an increased susceptibility to peroxide-induced hemolysis
also in the presence of normal levels of vitamin E [159]. Peters and
Kelly [160] observed that RBC vitamin E concentrations were below
the normal range in almost all unsupplemented patients and rose
into the normal range with a 1-year supplement of 100 mg per day,
but not 15 mg per day. Since RBC vitamin E concentration has been
shown to correlate well with tissue concentrations of the vitamin in
animals, tissue levels of vitamin E are expected to be lower than nor-
mal in CF patients.
Bioavailability of fat-soluble vitamin is limited in CF. Vitamin E
deﬁciency of CF is also associated with hypocholesterolemia [7]. As
a consequence, the relative deﬁciency of this vitamin is compensated
when the absolute levels are normalized for cholesterol levels, and
this suggests a poor transferring of this vitamin in the circulation by
a defective lipid and lipoprotein metabolism. Pancreatic insufﬁciency
and the consequent lipid malnutrition cannot completely explain this
defect and other, possibly CF-speciﬁc, dysfunctions could play a role.
Liver metabolism and speciﬁc plasma transport systems of this vita-
min need further elucidation in CF.
As a consequence of these aspects, it is not presently clear which
form and level of supplementation of this vitamin is most appropriate
to treat these patients. Usingα-tocopherol as a vitamin E supplement,
Peters et al. [160] reported that 100 mg per day are required to nor-
malize RBC concentrations. Other authors described unsuccessful
supplementation protocols with higher doses and this has led to de-
velop formulations with higher bioavailability in order to achieve bet-
ter compliance to oral supplementation (see below and the literature
reviewed in [161–163]).
Besides absorption and tissue delivery issues, speciﬁcity of action
is another critical item of antioxidant therapy with fat-soluble agentsin CF. As further addressed below, this aspect could be themain limit to
a successful use of natural forms of vitamin E in the clinical manage-
ment of CF inﬂammation even if a local lung-targeted therapy would
be developed according with so far proposed pre-clinical models of
aerosolized vitamin E [164,165].
Current pharmacological research is aimed to develop synthetic forms
of this and other fat-soluble antioxidants with better radical scavenging
properties at the lipid–water interface. Type of ROS target and the sites
of action greatly inﬂuence the chances of a fat-soluble antioxidant of alle-
viating oxidative stress in the airways as well as in other organs such as
liver and pancreas. These aspects dealing with speciﬁcity of action
[163,166,167] have stimulated the search of novel vitamin E-derived an-
tioxidants that may help to scavenge radicals at the lipid–water interface
of the epithelial cell membrane and surfactant. Amine derivatives
of tocopherols and tocotrienols have been recently demonstrated to
show higher antioxidant and free radical scavenging activity than α-
tocopherol [168]. Further in vitro pharmacological analysis has included
toxicity evaluations and the detailed investigation of scavenging of azo-
and phenolic radicals with different degrees of hydrophobicity, and the
inhibitory activity on IL-8 gene expression and phospholipase activity
in CF cells. Comparative evaluation with other synthetic derivatives,
such asα-tocopheryl succinate and natural forms of vitamin E, suggested
that these amine derivatives are promising antioxidant and anti-
inﬂammatory agents [Galli F. and Pilolli F., unpublished observation]
deserving further pre-clinical investigation in CF model systems.
Anti-inﬂammatory effects of natural and synthetic analogues of vi-
tamin E are also an intriguing pharmacological opportunity currently
under investigation by several laboratories [169,170].
Recently, vitamin E supplementation has been at the center of a
dispute regarding its safety when used at high dosages in certain
populations of patients. An extensive and speculative debate originat-
ed on this subject after a meta-analysis study byMiller et al. [171] that
examined the largest secondary prevention trials on vitamin E trials in
cardiovascular patients ﬁnding a signiﬁcantly increased mortality risk
for all the causes (about 4%, 1–8% in the 95% interval of conﬁdence)
when the patients were treated with doses >400 IU/die (that are
equivalent to 400 mg/die of the synthetic form allrac-α-tocopherol
and to 185 mg/die of the natural form RRR-α-tocopherol). This debate
resulted in a careful examination of this meta-analysis study by several
other authors and in further revisions of the literature on vitamin E tox-
icity in humans [see the literature recently reviewed in [163,172–174]]
that clearly demonstrated the poor consistency of the conclusions
raisedwithMiller'smeta-analysis study and the paucity of the concerns
that derived from that. These conclusions have been veriﬁed in the re-
cent international symposium on vitamin E of the Society for Free Rad-
ical Research, Europe branch of Rome 2009 [173,175]. Vitamin E used as
supplement for humans in all its forms (e.g. α-tocopherol and other
tocopherols and tocotrienols) is safe in abroad range of intakes
[172,176]. The tolerable upper intake level (UL) and the Acceptable
Daily Intake (ADI), established by the Joint FAO/WHOExpert Committee
on Food Additives for the natural form of vitamin E as α-tocopherol
equivalents are of 300 mg/die and 0.15–2.0 mg/kg body weight/die,
respectively [172,177].
3.5.2. Carotenoids
Levels of plasma carotenoids such as β-carotene, β-cryptoxanthin,
and total lycopene are signiﬁcantly lowered in CF patients and this
was associated with higher susceptibility to lipid peroxidation
[5,178–180]. Rust et al. [178] demonstrated that the long-term oral
supplementation with 50 mg β-carotene/day (i.e. 1 mg β-carotene/
kg BW/day) restored the levels of this carotenoid, while sub-optimal
supplementation was observed at doses of 10 mg β-carotene/day or
lower, thus conﬁrming the need of high doses of this fat-soluble factor
to overcome the limited absorption and thus to achieve plasma con-
centrations of healthy control subjects. Successful high-dose treat-
ments appear to lower oxidative stress markers such as TBA-MDA
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another study, β-carotene supplementation was observed to de-
creased lipid peroxide formation as quantitated by malondialdehyde
concentrations in plasma (TBA/HPLC method), and to enhance the re-
sistance to copper(II) ion-induced oxidation of low density lipopro-
teins [180].
At the same time, toxicity issues have been raised for human sup-
plementation with carotenoid formulations and particularly of water-
miscible formulations of preformed vitamin A that is regularly sup-
plemented to CF patients, which may increase serum retinol and
possible risk of CF-associated liver and bone complications (reviewed
in [161,181]). However, β-carotene supplementation seems to be safe
since this does not affect plasma concentrations of other carotenoids
and retinol, as well as of other fat-soluble vitamins as α- and γ-
tocopherol [178]. Recent studies designed to test the clinical efﬁcacy
of a CF tailored multivitamin formulation (commercial name AquA-
DEKs®), also tested the safety of this type of formulation and demon-
strated that this does not increase vitamin A above the normal levels
observed in healthy controls [162,182,183]. The normalization of β-
carotene levels obtained in these studies was associated only with
minor improvements on respiratory and growth parameters, while
the levels of urinary F2-IsoPs used as index of lipid peroxidation
were not affected [162]. The surrogate marker of lipid peroxidation
MDA was affected together with some selected antioxidant parame-
ters (RBC thiols and superoxide dismutase) in another study in
which this multivitamin formulation was preliminarily evaluated in
comparison with standard formulations of vitamin E and A [182].3.5.3. Coenzyme Q-10
Coenzyme Q-10 (Q10) is a well-known electron transporter in the
mitochondrial respiratory chain with fundamental role in cellular
bioenergetics and scavenging of radical species [184]. This lipophilic
substance is present in the circulation at low levels (serum concentra-
tions≤2 μM) mainly as ubiquinol-10, e.g. the reduced form, with an
approximate ratio of 95:5 with the oxidized form ubiquinone-10
[185,186]. A mechanism for a preferential distribution and accumula-
tion in mitochondria has been suggested for both the reduced and ox-
idized forms of CoQ10 that are taken up by the cells in a time- and
concentration-dependent. Subcellular localization and trafﬁcking of
exogenous Q10 are similar to those of the endogenous form, but
were different from that of α-tocopherol that is related with lipid
composition, particularly in the mitochondrial and microsomal frac-
tions [184]. Ubiquinol-10 readily oxidizes ex vivo by the reaction
with other lipophilic antioxidants such as α-tocopherol and butylated
hydroxytoluene [185]. Therefore a higher reduction potential than
other physiological fat-soluble antioxidants such as vitamin E and a
selective metabolism and cellular trafﬁcking, show peculiar role for
the cell CoQ which may also represent an important lipophilic antiox-
idant in cells and body ﬂuids.
Human cells synthesize this coenzyme through the cholesterol bio-
synthesis pathway so thatmore than two thirds of the tissue levels ap-
pear to have an endogenous origin; dietary sources provide a
contribution to Co-Q10 levels of blood and all solid tissues that varies
depending on the dose applied and type of dietary source [187]. How-
ever, in the case of oral supplements, it has to be considered that hy-
drophobicity and large molecular weight of this coenzyme inﬂuence
its absorption that ultimately is slow and limited [186,187]. Likewise
to vitamin E pharmacokinetics [188,189], Co-Q10 showed T(max) of
around 6 h that coincides with that of dietary lipids. Elimination is
close to that of the more retained form of vitamin E in human body,
e.g. α-tocopherol, with a half-life of about 33 h, which suggests poor
hepatic metabolism. However, commercially available formulations
are reported to be safe even at high doses and solubilized formulations
show enhanced bioavailability. In healthy subjects plasma Q10 re-
sponse to oral ingestion show saturation proﬁles with a plateau at adose of 2400 mg and the higher plasma concentrations were found
to facilitate uptake by peripheral tissues and also the brain [186,187].
Laguna et al. [190] recently investigated total serum levels of
coenzyme Q-10 in a wide population of CF children (n=381) and esti-
mated their association with clinical outcome. Near to 50% of these CF
patients were deﬁcient of Co-Q10 and this defect was signiﬁcantly
more prevalent in patients with pancreatic insufﬁciency and signiﬁ-
cantly associated with P. aeruginosa colonization in infants (under
24 months of age). Importantly, low Co-Q10 levels correlated to other
lipid markers of a poor nutritional status, such as total lipids and also
the other fat-soluble antioxidants β-carotene and α-tocopherol,
which conﬁrms the presence of a common defect in the absorption
and metabolic pathways of this coenzyme with dietary lipids.
The deﬁcit of Co-Q10 may contribute to the impaired energy func-
tion of mitochondria of CF tissues and this may exacerbate CF-linked
inﬂammation, infection and cellular stress response of the lung. A sys-
tematic analysis of molecular lesions in CF bronchial tissue has been
recently carried out by proteomic approach [191]. Comparative eval-
uation of protein expressional pattern in CF and healthy control
tissues has revealed aberrant levels of some mitochondrial and
energy-related proteins in CF specimens that included the ubiqui-
nol–cytochrome c reductase complex core protein I and one form of
nidogen, a pseudogene of aconitase 2. These changes in CF may reﬂect
molecular changes which could be associated with an altered mito-
chondrial homeostasis and Co-Q10 redox.
Multivitamin supplements with high bioavailability containing
Co-Q10 have demonstrated to correct the deﬁcit of this antioxidant
and were preliminarily observed to improve airway inﬂammation
markers in CF patients [183]. However, further clinical investigation
failed to demonstrate that such an improved biochemical proﬁle is
associated with signiﬁcant improvements in weight percentile and
pulmonary function [162].
3.5.4. Fatty acids
A key pathophysiological role in sustaining inﬂammation in CF has
been attributed to the abnormal polyunsaturated fatty acid (FA) pat-
tern. Abnormalities in FA proﬁling are potentially linked to CFTR
mutation-driven alterations in the absorption and/or metabolism of
dietary lipids [192,193], and to the consumption of high oxidizable
FA involved in the free radical-mediated lipid peroxidation [7].
Among those alterations, dysregulation of the docosahexaenoic acid
and arachidonic acid balance has been extensively studied with re-
portedly signiﬁcant reduction of DHA in CF and a parallel increase
in the levels of AA and inﬂammatory indices [193–195]. Actually, AA
is the progenitor of both enzymatic- and free radical-derived inﬂam-
matory mediators, including leukotrienes, prostaglandins and iso-
prostanes. On the other hand, n-3 PUFA (eicosapentaenoic acid and
docosahexaenoic acid) are involved in the generation of potent medi-
ators, namely resolvins and protectins, which are able to resolve
exudates and to act as organ protective and antiﬁbrotic. Secondarily
to their anti-inﬂammatory action, n-3 FA may also produce an
antioxidant-like response (e.g. a reduced demand of antioxidants to
achieve an optimal control of oxidative pathways). As a consequence,
n-3 PUFA have been suggested and widely used as supplements in CF
patients usually under the form of ﬁsh oil [196–198]. It is worth of
note, however, that defective levels of DHA in CF patients was not
conﬁrmed in recent studies [7]. It was also shown that patients on
DHA supplements did not have increased plasma n-3 FA concentra-
tions, but showed more severe oxidative stress compared to the
unsupplemented patients [7]. This observation of an increased risk
of oxidative stress in CF subjects receiving n-3 fatty acids supple-
ments has also been described by other authors [199].
Studies reporting increased AA levels in CF patients have been
contradicted by others [7,200,201] thus contributing to weakening
the pathophysiological role of the altered DHA–AA balance as turn
point of an upregulated inﬂammatory status in CF. In this context, a
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[202] highlighted the lack of evidence for a signiﬁcant correction of
the assessed clinical end points (mainly respiratory symptoms)
even when inﬂammatory indices and other laboratory end points
were met. Taken together, these data suggest that there is insufﬁcient
evidence to draw ﬁrm conclusions or recommend routine use of n-3
supplements in CF. Notwithstanding, it is common belief that n-3
supplements provide some beneﬁts for people with CF with relatively
few adverse effects and thus their use is not discouraged.
Further alterations in fatty acid metabolism have been highlight-
ed, including the consistent ﬁndings of an increase in circulating
levels of saturated and monounsaturated fatty acids [7,203,204].
Decreased levels of essential FA (EFA), i.e. the FA that have to be in-
troduced with the diet, correlates with the severity of respiratory
insufﬁciency and the same clinical correlation was observed with al-
tered proportions of FA species converted by the activity of desatur-
ase enzymes (reviewed in [204]). The close relationship between
certain fatty acids and oxidative stress, including the negative correla-
tion of C24:0 and linoleic acid with oxysterol levels point to the need
of intensive investigation in CF patients of previously neglected lipid
species that are emerging candidates in the control of metabolism.
Quantitative lipidomic analyses have lead to identify C16:1n7 palmi-
toleate as a “protective” adipose-derived lipid hormone that strongly
stimulates insulin activity in muscle and liver, also suppressing in-
ﬂammatory cytokine output from mice fat cells [205]. Speciﬁc meta-
bolic activities have been also demonstrated by medium chain
saturated fatty acids, caprylic acid (C8:0), capric acid (C10:0) and lau-
ric acid (C12:0). Capric acid acts as a direct ligand of PPARγ, using a
binding pocket different from the binding pocket of thiazolidinedione
or long chain fatty acids [206]. Additional activities of medium chain
fatty acids, which are ligands of free fatty acids receptors detected
in the immune cells, the gastrointestinal tract, and adipocytes, may
contribute to metabolic homeostasis and inﬂammatory responses
[207]. These data underscore the importance of a lipid-mediated “en-
docrine network”, demonstrating how speciﬁc alteration of one or
few serum lipids would be per se sufﬁcient to inﬂuence metabolic ho-
meostasis. Given the relevance of this emerging information and the
alteration of lipid metabolism and inﬂammatory status in CF, fatty
acid lipidomics need to be deeply investigated in CF.
Again, these studies have obvious nutritional implications. Satu-
rated fatty acids with chain lengths higher than C18 are poorly
absorbed partly because they form insoluble calcium salts [208].
Medium chain saturated fatty acids are well known for being highly
absorbed through the intestine, providing rapid delivery of energy
via oxidation of the more hydrophilic short chains, and have been
suggested to provide proper nourishment in patients with CF [209].
Recent studies have shown that consumption of a high-fat diet rich
in medium chain fatty acids, as opposed to long chain fatty acids,
does not lead to ectopic fat accumulation in skeletal muscle and
liver of both rats and mice [210]. In light of the close association be-
tween nutritional status, inﬂammation and life expectancy in CF pa-
tients, the manipulation of dietary lipids in these patients must be
further explored as a possible strategy to provide adequate nutrition
and better management of oxidative stress.
3.6. Hydrosoluble antioxidants, oligoelements and enzymatic antioxidants
3.6.1. Vitamin C
Vitamin C status in CF patients has been poorly investigated. Early
studies suggested a defective vitamin C status that was refractory to
oral supplementation [211]. Other and more recent studies showed
normal or slightly decreased levels of vitamin C in CF patients as com-
pared to healthy controls, but age- and disease-related decline of this
water-soluble antioxidant was reported in these patients [5,212].
In the study of Winklhofer-Roob et al. [212] on mid-European CF
patients vitamin C concentrations decreased with age with anestimated rate of 5 μmol/l/yr and vitamin C concentrationsb40 μ-
mol/l were associated with highest indexes of inﬂammation which
is consistent with the hypothesis that optimal levels of vitamin C
may inﬂuence immuno-inﬂammatory activity of alveolar macro-
phages and neutrophils. Other few studies have examined the effect
of supplements containing vitamin C on CF inﬂammation and oxida-
tive stress since the levels of this vitamin do not signiﬁcantly improve
with supplementation (reviewed in [213]). This highlights the com-
mon fate that this hydrosoluble vitamin shares with several fat-
soluble counterparts in the “micronutrient paradox” of CF patients in
which the need for a correction of their status along the progression
of the disease is frustrated by the poor efﬁcacy of oral supplementa-
tion protocols. Formulations and appropriate supplementation proto-
cols that may produce a better correction of vitamin C status of CF
patients are awaited for further clinical evaluation.
3.6.2. Selenium and selenium-dependent peroxidases
Selenium is a trace element with marked electrophilicity [214]
that once converted to the organic form of Se-Cys can be introduced
in protein structures to play its important role in H2O2 metabolism
and signaling [215]. As catalytic center of the enzyme GSH-
peroxidase (SeGSH-Px), Se plays a crucial role to protect polyunsatu-
rated lipids of plasma membrane and circulating lipoproteins form
peroxidative insults. With other Se-proteins such as the high molecu-
lar weight thioredoxin reductases, this oligoelement participates to
the control of protein thiol-disulﬁde oxidoreduction and glutathiony-
lation, which regulate signaling pathways of crucial importance in the
regulation of immunity and inﬂammation [16] but also the function-
ing of other redox-sensitive proteins such as the same CFTR [124].
The activity of SeGSH-Px in blood is considered a functional as-
sessment of selenium status, even if this assumption has some limita-
tions related with the saturation proﬁle that the Se stores show at
increasing doses of Se administration. Investigations of the selenium
status in CF patients have produced conﬂicting ﬁndings, which may
depend on differences in dietary intake, ethnicity and environmental
factors in the diverse patient populations (reviewed in [216,217]). CF
children have been reported to have lowered blood selenium and RBC
SeGSH-Px activity [218,219], normal plasma selenium and lowered
RBC SeGSH-Px [220] and even normal levels of both these two param-
eters [221]. The supplementation with selenium in combination with
other antioxidants was observed to increase the concentrations of
blood selenium that, likewise β-carotene and fatty acid, were posi-
tively correlated with improved lung function [6].
Foucaud et al. [218], observed that a defective selenium status
was associated with lowered levels of other antioxidants that contrib-
ute to the anti-peroxidative activity of this microelement, such as
vitamin E (reviewed in [222]), and the severity of this deﬁciency
was lower in children with pancreatic enzyme replacement and vita-
min E supplementation.
Treatments to substitute for exocrine pancreatic insufﬁciency by
pancreatic enzymes from animal sources, such as porcine pancreas,
have been conﬁrmed to be a source of Se [220]. These affects RBC
SeGSH-Px activity and plasma selenium concentrations, which has
to be taken into account when selenium supplements are given to
CF patients.
Selenium has been used to develop a series of organoselenium
compounds that may open the way to new therapeutic opportunities
in CF (see Section 3.9.2). These include GPX mimetic drugs and phase
II enzyme inducers, which may provide higher antioxidant activity of
ASL and cellular protection effects in the airways.
3.6.3. Zinc and copper
Zinc and copper (Zn and Cu, respectively) are present in many
proteins so that a deﬁciency of these trace metals could have pleiotro-
pic effects in humans. As regards antioxidant systems, these two oli-
goelements contribute an important role being cofactors of two
703F. Galli et al. / Biochimica et Biophysica Acta 1822 (2012) 690–713isoforms of the superoxide dismutase enzymes, e.g. the extracellular
form, e.g. the EC-SOD or Sod 3 and the Cu–Zn-SOD or Sod 1 that is
found in several tissues and cells [223]. The EC-SOD exerts its antiox-
idant role also in the lining ﬂuids of the airways [224].
The notion that CF patients have defective concentrations of blood
Zn and Cu is controversial. As far as Cu status is concerned, few data
have been produced and are available in the literature suggesting
the notion that CF patients develop a moderate copper deﬁciency
[225,226]. That was essentially demonstrated on the bases of a defec-
tive activity of Cu-related proteins such as plasma ceruloplasmin,
diamine oxidase, and RBC SOD. This defect seems to be refractory to
Cu and Zn supplementation (see below).
More advanced studies have been carried out in the case of Zn sta-
tus in CF. Low plasma zinc concentrations were reported in approxi-
mately 30% of young infants with CF identiﬁed by newborn
screening [227], and an impaired zinc homeostasis in CF patients
was described by Easley et al. [228]. This is characterized by poor con-
servation of the endogenous pool with fecal loss and impaired frac-
tional absorption of zinc, which are the consequences of pancreatic
insufﬁciency and persisting steatorrhea. These studies suggested
that in the clinical management of CF patients these defects can be
at least in part corrected by exocrine pancreatic enzyme replacement.
A series of studies by Van Biervliet et al. [229,230] demonstrated
in a Dutch population of CF infants and children that serum Zn varies
in an age-dependent manner, but remained unchanged with respect
to healthy control levels. In CF patients no difference in serum Zn con-
centration between pancreatic-sufﬁcient or pancreatic-insufﬁcient
patients was observed and no correlation was found with the nutri-
tional status or height z-score. Importantly, in these studies a signiﬁ-
cant correlation of serum Zn was observed with the fat soluble
vitamins A and E, thus conﬁrming the relationship between the ab-
normalities of lipid and Zn metabolism in CF. This suggests that co-
supplementation of Zn and fat-soluble vitamins should be advised
in the presence of pancreatic insufﬁciency and persisting steatorrhea.
Neve et al. [219] in a study aimed to assess plasma and erythrocyte
zinc, copper and selenium in CF children, showed that mean plasma
zinc and copper levels were not different from those in age-
matched controls which conﬁrms the observations by Van Biervliet
et al. described above. However, plasma zinc concentrations de-
creased in patients with moderate-to-severe growth retardation and
with severe pulmonary disease, but very low zinc levels occur sporad-
ically. Erythrocyte zinc and copper levels were signiﬁcantly higher
than normal, while RBC selenium was lower than in age-matched
controls. These trace element concentrations in erythrocytes were
discussed in relation to the activities of the Cu/Zn-SOD and the Se-
enzyme GPx. This observation suggests a compensatory upregulation
of the erythrocyte Cu/Zn-SOD by the exposure of erythroid precursors
to ROS and/or other CF-related stressors.
Best et al. [225] also studied RBC SOD activity using this as a bio-
logical sensor of Cu status in CF patients. A lowered activity of this
enzyme was reported in CF together with that of the other Cu-
dependent enzyme plasma diamine oxidase, while plasma ceruplas-
min showed normal activity. Degradation rates of copper proteins
are known to be accelerated in conditions of copper deﬁciency,
which could explain the ﬁnding at least in part. Anyway, when Cu
and Zn were supplemented to CF patients either separate or in
combination (6 weeks of 3 mg copper/d as copper-glycinate and
30 mg zinc/d as zinc-glycinate), any of the copper enzyme activities
was affected. Therefore the moderate copper deﬁciency of CF patients
appears to be refractory to the intervention by increased copper and/
or zinc intake.
Erythrocyte Cu/Zn-SOD and the plasma levels of Cu and Zn were
also measured in the study of Wood et al. [6] in which Australian CF
patients (age>5 years) were treated with a high-dose antioxidant
multivitamin formulation containing 200 mg vitamin E (as RRR-α-
tocopherol), 300 mg vitamin C (as sodium ascorbate), 25 mg β-carotene (all-trans isomer), 90 μg Se (as selenomethionine), and
500 μg vitamin A (as retinyl palmitate) in oil. Plasma oligoelements,
and particularly Zn, were in the normal range at baseline (as com-
pared with the data reported in [229,230]) and were not affected by
this multivitamin supplement. The same was found for the activity
of RBC SOD and for plasma 8-iso-PGF2α as surrogate biomarker of
lipid peroxidation.
In a recent non-randomized small population (n=21) case–con-
trol study in CF children, Zn supplementation was proven to produce
positive clinical effects in Zn-deﬁcient patients [196]. The supplemen-
tation with 5 mg/kg Zn sulfate/day (maximum 150 mg), signiﬁcantly
decreased the number of infections and increased the forced expira-
tory volume in 1 s; energy intake and growth parameters also im-
proved. These parameters were unaffected in untreated patients
except that in the case of the pulmonary function that decreased sig-
niﬁcantly. These clinical observations on Zn supplementation need to
be conﬁrmed in prospective double-blind randomized control trial.
3.7. Appropriateness and targeting of antioxidant therapies in CF
The choice of the appropriate antioxidant and dose to correct a cer-
tain biomarker and its associated biochemical lesion is another impor-
tant point that appears to have disregarded in many clinical studies.
For instance, unlike vitamin E, vitamin C supplementation does not
alter F2-IsoPs levels in humans (reviewed in [74]). This appears to
be true also in the antioxidant therapy of CF in which vitamin C
(300 mg/day) was administered together with other antioxidants
that included a dose of vitamin E of 200 mg/day, without any signiﬁ-
cant effect on the surrogate biomarker of lipid peroxidation F2-IsoPs
[6]. When carotenoids are used as supplements to prevent the damag-
ing action of ROS in the CF airways, it is noteworthy that these are not
particularly good quenchers of peroxyl radicals relative to phenolics
and other antioxidants, but are exceptional in quenching singlet oxy-
gen, at which most other phenolics and antioxidants are relatively
ineffective. Singlet oxygen is not a radical and does not react via radi-
cal mechanisms, but reacts mostly by the addition to double bonds,
forming endoperoxides that can be reduced to alkoxyl radicals that ini-
tiate radical chain reactions typical of the peroxidative damage of PUFA
[38]. In this case the analysis of F2-IsoPs, lipid peroxide formation and
transition metal-induced oxidizability of lipoproteins [162,180] are all
appropriate to evaluate the effect of carotenoids in preventing lipid
peroxidation.
As far as the dose is concerned, clinical pharmacology of vitamin E
as an antioxidant was recently investigated by means of the effect on
F2-IsoPs production, and doses of α-tocopherol of 1600 IU/day or
greater were found to be required to statistically affect plasma F2-
IsoPs levels in hypercholeterolemic subjects [176]. Several vitamin E
supplementation studies in CF patients have been performed with
doses of lower than 300 IU/day regardless of the lowered absorption
by pancreatic and liver defects, and the regular supplementation
with these doses does not appear to correct lipid oxidation markers
in CF [7].
In the clinical practice and planning trials it has to be taken into
consideration that, in spite of substantial evidence supporting a
higher antioxidant demand in CF, interventions with several antioxi-
dant formulations produce poor responsiveness particularly in the
case of fat-soluble antioxidants, which are poorly absorbed [6,162].
Since many oxidants and antioxidants are present in tissues
and biological ﬂuids and these have different chemical and physical
characteristics, the possibility to produce a successful therapy with
a single antioxidant molecule is too far to be realistic. Moreover, an-
tioxidants act by multiple mechanisms in a single system or by a
different single mechanism depending on the reaction system
responding in a different manner to different radical or oxidant
sources. Because multiple reaction characteristics and mechanisms
as well as different phase localizations are usually involved, no single
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ROS sources. The defect of physiological antioxidants may also interfere
with antioxidant therapies that are based on one or few exogenous
antioxidants.
Moreover, several antioxidant vitamins such as vitamin E and ca-
rotenoids have multiple natural forms with different bioavailability,
metabolism and bioactivity [157,167,231]. As far as the case of vita-
min E supplementation concerns, α-tocopherol was used as unique
vitamer in the large majority of supplementation trials so far per-
formed and is the form used in the nutritional management of CF
patients. Moreover, several supplements contain the synthetic (or ra-
cemic) form of this vitamin that has lower bioavailability than the
natural form. Other forms present in nature and abundantly con-
tained in vegetables such as tocotrienols and the less methylated
forms of tocopherol are not represented in many of the supplement
formulations so far available in clinical centers, and the supplementa-
tion with α-tocopherol also limits their bioavailability. These forms
show markedly higher susceptibility to hepatic metabolism and bili-
ary excretion with respect to α-tocopherol, e.g. the most represented
form in blood and solid tissues, and if co-supplemented, these are
easily displaced during liver uptake and excreted with bile by
means of competition with the same α-tocopherol. Notwithstanding,
these minor forms have been proposed to play important physiolog-
ical roles showing molecular characteristics, transcriptional effects
and antioxidant activities that clearly differentiate them in subfam-
ilies with distinct biological functions. Some of these, such as α-
tocopherol, e.g. the second vitamin E form as relative abundance in
blood, and its carboxyethyl-hydroxychroman metabolite [189], ap-
pear to have health-related anti-inﬂammatory effects which are par-
ticularly relevant in lung protection [232,233]. This has suggested
that such a group of “non-α-tocopherol” forms may represent anoth-
er family of vitamins within the family of vitamin E with an impor-
tant, but often missed, contribution to the proposed health effects of
this vitamin [163].
These aspects may thus limit the possibility to provide CF patients
of optimal levels of this vitamin in all its components, even if they are
regularly treated with a vitamin E supplement, e.g. withα-tocopherol.
Targeted antioxidant therapy with formulations with higher bio-
availability and bioactivity has been anticipated in CF. New antioxi-
dant formulations have been proposed to overcome main limits of
antioxidant therapies so far proposed for these patients. Water-
miscible α-tocopheryl acetate containing polysorbate, propylene gly-
col or polyethylene glycol as emulsiﬁers form micellar structures
were suggested to providing greater bioavailability than the fat-
soluble counterparts. These were commercialized with the brand
names of E-vimin®, Cremophor® EL and Aquasol® E, but despite
the original positive expectation [234,235], some studies failed to ob-
serve a higher response in vitamin E levels when these were com-
pared with fat-soluble formulations [236,237].
In a pilot study by Papas et al. [183] a micellar formulation of fat-
soluble nutrients and antioxidants was found to improve plasma
levels of β-carotene, γ-tocopherol and CoQ(10), reducing at the
same time some inﬂammatory markers in induced sputum, e.g. mye-
loperoxidase and to a lower extent PMN elastase and total cell counts,
while lung function and sputum bacterial counts were unaffected.
The same group recently conﬁrmed the possibility to increase the ab-
sorption of fat-soluble micronutrients using formulations with higher
bioavailability speciﬁcally designed for malabsorbing patients such as
CF patients that include also vitamin K and commercialized with the
brand name of AquADEKs® [162]. Despite improved vitamin and mi-
cronutrient levels, in this non-randomized, open-label study, AquA-
DEKs® produced only modest improvements in weight percentile
and pulmonary function. Another recent pilot observation [182] has
suggested the beneﬁcial effect of this formulation on antioxidant and
oxidative stress parameters of this oral supplement that surely deserves
more clinical investigation by larger randomized controlled trials.Recent multivitaminic formulations have been designed to contain
also the minor forms of vitamin E and speciﬁcally γ-tocopherol [238],
the expected superiority of which with respect to formulations con-
taining only α-tocopherol needs to be veriﬁed. As discussed above
in the section dedicated to vitamin E, further advancements in the
therapy of CF inﬂammation and oxidative stress could be based on
synthetic forms and natural metabolites of this vitamin that have
been recently identiﬁed to possess higher antioxidant and also anti-
inﬂammatory activity than α-tocopherol (reviewed in [163,168]).
Pre-clinical investigation of these and other fat-soluble agents is
currently addressed to develop formulations and administration pro-
tocols that may increase the therapeutic efﬁcacy in the airways. In the
antioxidant therapy of lung dysfunction in CF, local administration
protocols may overcome the limits of oral and systemic administra-
tion protocols, increasing bioavailability and providing targeted
approach to inﬂammation and oxidative stress. Aerosolization of vita-
min E and other fat-soluble micronutrients is possible and may allow
direct administration in the airways to prevent toxicity of smoke
which is closely associated with inﬂammation and oxidative stress
[164,165]. To our knowledge, this as well as other strategies of local
administration such as instillation of solutions such as surfactant-
like solutions enriched of vitamin E, have not been previously inves-
tigated in CF patients and other CF model systems.
On the contrary, inhalation is an administration route widely
adopted in the case of GSH and NAC therapy described above. In
this context, Cys formulations alternative to NAC have been proposed
for use as antioxidant and anti-inﬂammatory agent for inhalation.
Nacystelyn is a lysine adduct of NAC that thanks to a higher proton-
ation equilibrium shows increased water solubility and thus better
bioavailability. Nacystelyn has been described to inﬂuence IL-8 gener-
ation and the inﬂammatory signaling of bronchial epithelial cells
[239] and preliminary clinical evaluation has demonstrated the safety
of this drug [240]. Further clinical trials aimed to assess the effect on
lung symptomatology of CF patients are needed. Direct administra-
tion in the airways could also be adopted for micronutrient vitamins
with poor absorption and bioavailability due to GI defects.3.8. Clinical impact of antioxidant therapy in CF
Huge in vitro and pre-clinical evidence has provided the rationale
to support clinical investigation of antioxidant strategies in CF. These
should aim to restore the oxidant–antioxidant balance of CF airway
challenged by chronic infection and inﬂammatory cell activation.
Some observational trials have conﬁrmed that antioxidants used
as either supplements to the diet or drugs for lung administration
by aerosolized formulations, may help in relieving progressive lung
damage and other adverse clinical events of CF such as poor growth.
So far, few studies have examined with sufﬁcient methodological
rigor the clinical efﬁcacy of antioxidant therapy in CF. This was also
concluded in a previous review of the literature by Cantin et al. [12]
that was published in the beginning of 2006 and is conﬁrmed also
in a recent analysis of clinical trials on antioxidant therapy in CF pa-
tients [213] that examined the literature until September 2010
using as sources the databases of the Cochrane CF and Genetic Disor-
ders Group CF Trials Register, PubMed, CINAHL and AMED. Useful in-
formation was retrieved from just four randomized controlled trials
and one quasi-randomized controlled trial on vitamin C, vitamin E,
β-carotene and selenium used as supplements administered alone
or in combination. Post-hoc data analysis that was possible only in
three studies on a total of 87 CF patients, showed the absence of
any signiﬁcant improvement in lung function that was selected as pri-
mary outcome together with quality of life that improved in one trial.
Secondary outcomes concerning laboratory indices of oxidative stress
and antioxidant status showed several improvements. These included
an increase of RBC SeGPx by selenium supplementation done as
705F. Galli et al. / Biochimica et Biophysica Acta 1822 (2012) 690–713individual or combined supplementation, and increased levels of all
plasma antioxidants, except vitamin C, that were observed in all the
trials.
The message from these studies to pediatricians and nutritionists
within the clinical staff of CF centers is that in the absence of solid ev-
idence regarding the clinical effectiveness of oral formulations of an-
tioxidant supplements in CF (including PUFA), their use as a routine
clinical practice should be considered with caution keeping clear in
mind that this should represent just a complement of one of the
most critical interventions in the life-long clinical management pro-
gram of CF patients, e.g. providing an adequate nutriture [140]. In
this context, compensating energy and protein malnutrition has to
remain the ﬁrst goal of nutritional management programs. Providing
higher intakes of antioxidant micronutrients with food naturally-
enriched (or functionalized) of micronutrient antioxidants should
be preferred in order to have the higher combination of positive nu-
tritional factors that are lost during reﬁnement procedures and over-
all industrial processing of dietary supplements.
Measures of good practice in clinical management of micro-
malnutrition in CF patients would include the support of specialized
personnel and laboratories. The centers should have the possibility
to ascertain with appropriate nutritional and laboratory tests what
the level of deﬁciency is for the different micronutrients that each pa-
tient may suffer from during a dietary program. Monitoring dietary
intakes and blood levels of micronutrients is not sufﬁcient to set a
personalized nutritional intervention with supplements or functional
foods. Sub-optimal intakes and the compliance to nutritional inter-
ventions should be veriﬁed by means of selected biochemical and
clinical criteria. Unluckily, the latter are still not well established for
some micronutrients such as the fat-soluble vitamins E (reviewed in
[163,173,241]) and K [242,243], and also for trace elements such as
Se [244]. For many of the antioxidants used as supplements in
humans we still do not know exactly several of the biological effects
that these may provide when introduced in a healthy body and we
know less what these can do in disease. These aspects hardly impact
on the concept of optimal levels of intake that should be identiﬁed for
each micronutrient on an individual basis. According with the aspects
discussed in the previous sections, optimal levels of intake for antiox-
idant micronutrients are different in CF patients and healthy subjects
and vary with age and several individual factors.
Lung administration of antioxidants by means of aerosolized for-
mulations, so far used for GSH therapy (see above), is a promising
ﬁeld of clinical investigation in CF. Toxicity issues are currently the
main concern and the subject of clinical evaluation by several groups
(described above).
Information on future directions of antioxidant therapy in CF can
be inferred by the analysis of pending or recently completed clinical
trials that have been searched (December 2011) at ClinicalTrials.gov
database matching the terms “antioxidant therapy” or “glutathione”
with “cystic ﬁbrosis”. Fifteen trials were retrieved and those directly
related to antioxidant therapy (n=12) are presented in Table 1 and
include efﬁcacy and safety studies of inhaled drugs as GSH, sodium
pyruvate, NAC, and NO, and the dietary supplements: AquADEKs®,
an antioxidant-rich multivitamin supplement, epigallocatechin gal-
late (EGCG)/tocotrienol, curcuminoids, the amino acid glutamine,
sulforaphane in broccoli sprouts. One trial is investigating the ﬂavo-
noid quercetin as CFTR modulator.
3.9. Emerging antioxidant and anti-inﬂammatory approaches in CF
Mediterranean foods such as olive oil and red wine or several
plant extracts such as herbal tea or grape seed extracts contain a
series of natural compounds with important antioxidant and NO
scavenging activity that have been widely investigated for the pre-
vention of oxidative stress-related diseases [38,245]. These have
been long investigated as template molecules to develop antioxidantand anti-inﬂammatory drugs. Between the multitudes of natural sub-
stances, most investigated ones include for instance tyrosol, hydroxy-
tyrosol, gallic, and caffeic acids, belonging to the family of phenols,
while resveratrol of the stilbenes family, epicatechin, kaempferol,
and cianidin are examples of ﬂavonoids; examples of fat-soluble phe-
nolics are those of the family of tocols (vitamin E) and carotenoids. All
these compounds show different metabolisms and signaling effects
[246]. Antioxidant and cell protection mechanisms are associated
with different and sometimes concurrent processes as H-atom trans-
fer and electron donation, radical trapping and chelation of transition
metals that can be easily investigated at the chemical level [247]. Be-
sides these direct antioxidant effects, metabolic responses and signal-
ing effects of natural compounds are also important to produce
second-generation responses that modify the level of antioxidant
protection and the potential for ROS detoxiﬁcation in cells and body
ﬂuids. These derive from the transcriptional regulation of antioxidant
and pro-oxidant genes that coexist with the modulation of cytokine
secretion and inﬂammatory enzyme activities.
Some of these natural plant-derived antioxidants may provide fur-
ther pharmacological activities of possible relevance in CF. This is the
case, for instance, of the plant ﬂavonoids genistein, apigenin, kaemp-
ferol, quercetin and hesperidin [248–251] that fall in the pharmaco-
logical category of “potentiators” [252] in that these activate at least
to a certain extent CTFR-mediated Cl currents in normal and CF airway
epithelium investigated either in vitro or in vivo in humans and ani-
mal models. Actually, as prototypal ﬂavonoid-derived potentiator,
the tyrosine kinase inhibitor genistein potentiates the gating of wild-
type as well as ΔF508 CFTR and G551D CFTR [253], but at higher
doses it inhibits CFTR gating, which make this an unlikely clinical can-
didate. Similar potentiation effects have been reported for the antiox-
idant curcumin [250] that shows an additive effect with respect to
genistein-induced potentiation. Besides CFTR potentiation, which
does not appear to have a direct inﬂuence on GSH and nutrient trans-
port in the lung tissue, all these natural substances have been used
alone or in combination with other agents as in vivo enhancers of
lung antioxidant protection [246,254,255]. In the case of quercetin,
thiol-reactive phenolic [256], bronchodilation and anti-inﬂammatory
effects by a restoration of the Th1/Th2 balance have been reported
in inﬂammatory syndromes of the lung [255,257–259], but these
effects have not been explored in CF. Pyocyanin toxicity (see above
in the Section 2) could represent an issue for the use of quercetin
and other catechols in infectious diseases of the lung [260].
Other natural antioxidants of potential interest in CF therapy in-
clude terpenoids [261] such as terpinen-4-ol, a major constituent
of tea tree oil that is being investigated in the therapy of anti-
biotic resistant organisms, speciﬁcally against methicillin-resistant
Staphylococcus aureus (MRSA) [262], a problem in CF [263]. Other
than being lipophilic antioxidants, terpenes can prevent oxidative
stress of the CF lung secondarily to the antibiotic effect thereby pro-
moting a better control of immuno-inﬂammatory pathways and lung
antioxidants.
3.9.1. Targeting NF-κB with natural compounds: resveratrol and plant
extracts
Natural compounds were long known to be useful in designing
anti-inﬂammatory drugs and some of these could ﬁnd an application
in the control of the transcription factor kappa-B (NF-κB) that may
lead to develop advanced pharmacological tools to control inﬂamma-
tion and to produce higher antioxidant protection to CF airways.
Inhibitors targeting NF-κB, including transcription factors decoy
molecules (TFD), are potent down-regulators of gene expression
and release of IL-8 in CF cells infected with P. aeruginosa [264,265].
Resveratrol (3,5,4′-trihydroxystilbene, “E” form) is one of the most
investigated natural antioxidant with proposed activity as NF-κB
inhibitor. This is a phytoalexin present in large quantity in red wine,
preferentially in the skin of grapes, being its concentration
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Furthermore, resveratrol is a constituent of ‘Darakchasava’ (1.3–6 mg/
l), an ayurvedic medicine from India [267]. The antioxidant activity of
resveratrol has been reported in several papers and occurs also in lung
tissues, suggesting that resveratrol has potential as a therapeutic
agent in respiratory disease [268–270]. Resveratrol can be considered
one of the most interesting molecules from the natural world
exhibiting strong antioxidant activity that at the same time is able to
exert anti inﬂammatory activity through alteration of NF-κB functions
and efﬁcient inhibition of pro-inﬂammatory genes [271,272]. As far as
the effects on CF model systems are concerned, Cabrini et al. [26]
reported the effects of resveratrol on P. aeruginosa infected CF IB3-1
cells. The results obtained demonstrate that resveratrol exhibits minor
effects of IB3-1 cell growth and important inhibitory effects on accumu-
lation of IL-8 and GRO-α mRNA, while minor effects on IL-6 gene ex-
pression were observed. These data support recently published
observations suggesting inhibitory effects of resveratrol in infection-
mediated inﬂammatory processes [273]. Interestingly, resveratrol has
been reported as a potent inhibitor of NF-κB activity and a promising
anti-inﬂammatory agent [272,274] also in combinationwith othermol-
ecules [274,275]. However, in vivo translation of this pre-clinical on res-
veratrol is hard to be foreseen. This natural compound displays poor
bioavailability [276] and further characterization of resveratrol pharma-
cokinetics is troublesome since it is hardly measurable in vivo [277].
Furthermore, the regulation of inﬂammatory responses by resveratrol
has been suggested to be far more complex than simple direct suppres-
sion of NF-κB activity. Actually some aspects of the immune response
could be enhanced by this natural substance, which may lead to
hypothesize broad negative feedback events on immuno-inﬂammatory
pathways [278]. In any case, and with these cautions in mind, the pub-
lished observations on cellular model systems support the concept that
resveratrol and resveratrol-containing formulations deserve further con-
sideration to determine their possible therapeutic values in CF.
Other inhibitors can be identiﬁed from systematic studies of natural
products and their ability to interfere with NF-κB activity [279–281].
Recent studies have demonstrated that the whole extract of Aegle
marmelos (Rutaceae) has strong inhibitory effect on the P. aeruginosa-
dependent IL-8 induction in human CF-derived bronchial IB3-1 cells
without affecting cell proliferation [280]. Molecular analysis of compo-
nents contained in A. marmelos extracts revealed that three major com-
pounds, namely 5,6-dimethoxy-1-indanone, 2-hydroxy-cinnamic acid
and 5-methoxy psoralen (5-MOP), reproduce the inhibitory effect ob-
servedwith thewhole extract [280]. A further example has been recent-
ly published using extracts from bergamot (Citrus bergamia Risso). In
this study the extracts were characterized and the main detected con-
stituents were assayed for their biological activity [281]. The results
obtained demonstrated that the extracts from bergamot epicarps con-
tain components displaying an inhibitory activity on IL-8. Particularly,
the most active molecules were bergapten and citropten. These effects
have been conﬁrmed by analyzing mRNA levels and protein release in
the CF cellularmodels IB3-1 and CuFi-1 inducedwith TNF-α or exposed
to P. aeruginosa.
A parallel strategy linking NF-κB inhibition and down-regulation
of NF-κB-dependent functions is described in recently published
studies based on a structured-based virtual screening (VS) of differ-
ently substituted furocoumarins and analogues against NF-κB, with
the objective of selecting molecules able to inhibit the binding of
this transcription factor to DNA [282,283]. Novel compounds were
identiﬁed with this strategy as potent inhibitors of NF-κB dependent
biological functions, to be proposed for the control lung inﬂammation
occurring in patients affected by CF [282–284].
3.9.2. Scavengers and regulators of H2O2 and NO
3.9.2.1. Lactoferrin and OSCN¯. The impaired DUOX/LPO system of CF
patients could be the target of therapeutic strategies that mayproduce concomitant antimicrobial and antioxidant effects. This sys-
tem described above in Section 2.2 represents an important compo-
nent of innate immunity with a role in bactericidal defense and
regulation of H2O2 metabolism of airways [32]. CF patients have also
reported to show lowered LF levels in the ASL [37] that together
with a CFTR-dependent defective efﬂux of SCN¯ and LPO [36] may cre-
ate the environment for a sustained ﬂux of H2O2 and for the genera-
tion of highly reactive Fenton species [11,38]. An ideal therapeutic
intervention should restore the LPO-dependent generation of bacteri-
cidal OSCN¯ from DUOX-derived H2O2 and SCN¯ in the ASL to control
at the same time the microbial bioﬁlm and the ﬂux of H2O2 into the
ASL. An approach close to this therapeutic mechanism was recently
proposed for the drug Meveol®. This is a complex of LF and OSCN¯,
with proposed in vivo antimicrobial activity [285] to be evaluated
in clinical trials for the aerosol treatment of lung infections in CF
patients. The role for this drug in the control of H2O2 levels of ASL
remains to be investigated.
3.9.2.2. Organoselenium compounds. Organoselenium compounds
have been proposed as therapeutic agents useful in the antioxidant
therapy of inﬂammatory conditions. These include GPX mimetic mol-
ecules such as Ebselen® (2-phenyl-1,2-benzisoselenazol-3(2H)-one)
or other and more recently developed molecules that are still in
pre-clinical steps of evaluation [286]. Selectively and speciﬁcity of ac-
tion are main issues in the therapeutic mechanism of this candidate
antioxidant drug that thanks to the electrophilic properties of Se
[214] reacts with thiols to reduce H2O2 and other species. Moreover,
Ebselen® has been described to act as potent non-competitive inhib-
itor of extracellular nucleoside diphosphokinase (NDPK) having neg-
ligible effect on ecto-ATPase and adenyl kinase activities, which are
other players of the metabolism of extracellular nucleotides [287].
This enzyme together with other nucleoside di- and triphosphates
contributes to regulate several components of the mucociliary clear-
ance process (MCC) that protects the lung against infections via acti-
vation of epithelial purinergic receptors. The inhibition of NDPK by
this GPX-mimetic drug may also impact on the energy status of endo-
thelial cells [287]. This aspect could be further investigated as a cellu-
lar protection mechanism in the pulmonary epithelium of CF patients,
being the control of cell energy of fundamental importance to prevent
the activation of death pathways [288].
Further therapeutic mechanisms for these Se-derived drugs may
derive from the marked activity as inducers of phase II enzymes
such as quinone reductase (QR) and glutathione-S-transferase (GST)
[289]. This induction response also observed with other electrophils
and redox-active molecules, such as natural phenolic antioxidants,
could produce higher cellular protection by the acquisition of an
increased capability to detoxify endobiotics generated during oxida-
tive stress and inﬂammation [246].
3.9.2.3. Melatonin and GSNO as NOx regulators. Increased markers of
NO-derived biological damage are present in the CF lung suggesting
the abnormal reactivity of NOx in the inﬂamed lung of CF patients
[52]. However, an impaired metabolism and biological function of
NO in CF airways (see Section 2.3) suggests a cautious approach to
the use of agents that may inﬂuence the levels and chemical behavior
of NO-derived species (NOx) with possible impact on the physiologi-
cal roles of NO in vasodilatation, innate immunity and H2O2 metabo-
lism of the respiratory tract [290,291]. NO donors also appear to
inﬂuence CFTR function of alveolar epithelium and gland serous
cells [292,293].
Main physiological role of the pineal gland hormone melatonin is
the synchronization of circadian rhythms, including the sleep–wake
cycle, but several other functions dealing with immunomodulatory,
antioxidant and cellular protection effects have been identiﬁed
[294]. Melatonin receptor stimulation may also inﬂuence cyclic AMP
signaling and the regulation of CFTR ion channel [295,296].
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examined the effects of short term melatonin administration (3 mg
for 3 weeks) on sleep and oxidative stress markers in CF [297].
According with the expected pharmacological effect of this hormonal
substance, the treatment was successful in improving sleep indices.
At the same time, nitrite levels determined in exhaled breath conden-
sate (EBC) were reduced to suggest a better control of NOmetabolism
of CF airways (discussed above in Section 2.3), but these effects, how-
ever, were not associated with a signiﬁcant correction of isoprostane
as lipid peroxidation marker measured in EBC. Increasing dosages of
melatonin could be investigated for the pharmacological treatment
of oxidative stress and immune dysfunction of CF patients due to
the absence of adverse effects of this hormonal substance in humans.
The S-nitrosation reaction of thiols is another interesting aspect of
NO pharmacology [53] that may ﬁnd an application in the therapy of
lung complications of CF. This has been the case, for instance, of the
S-nitrosothiol GSNO that has been used safely in human trials
[298,299]. This endogenous nitrosothiol with proposed regulatory ef-
fect on the CFTR of lung epithelia [292,293], is well tolerated in pa-
tients with CF when administered by aerosolization and may
produce better oxygenation [299] thereby suggesting that therapy
aimed at restoring endogenous GSNO levels in the CF airway may
merit further clinical evaluation. Since the administered GSNO de-
composes as shown by the increased levels of expired NO in CF pa-
tients under treatment with this nitrosothiol [299], further
investigation should be addressed to ascertain whether GSNO thera-
py may merely correspond to a GSH therapy.
NO dependent effects on CFTR function should be considered to
evaluate mechanism of action and speciﬁcity of antioxidant therapies
that target NO metabolism and function in the CF airways.
4. Conclusions and future perspectives
The presence of clinical and biochemical symptoms of inﬂammation
and oxidative stress implies that CF patients have a higher demand of
antioxidant protection. The combination of the dysfunctional CFTR
with a lowered intake and absorption of dietary antioxidants produce
sub-optimal levels of protection from both enzymatic and non-
enzymatic defense systems. The former could be associated with a de-
fective glutathionemetabolism and lowered intake of sulfur-containing
amino acids and oligoelements such as zinc and possibly selenium,
while fat-soluble antioxidant vitamins, such as vitamin E and caroten-
oids, and the water-soluble vitamin C, are lowered than in healthy sub-
jects due to malabsorption and possibly higher consumption.
The increased antioxidant demand in CF patients should be even
higher in the presence of complications of the lung, pancreas and
liver. Lung comorbidity is particularly important in this context
being associated with recurrent infections, which results in the alter-
nation of inﬂammatory exacerbates and chronic inﬂammation. These
sustain the ﬂux of ROS in the airways and promote the formation of
second-generation byproducts by the damage of biomolecules such
as PUFA and proteins, which may diffuse also at the systemic level to
further promote adverse biological responses and toxic reactions. Pan-
creatic insufﬁciency causes malnutrition and may lead to develop en-
docrine and metabolic defects associated with diabetes of CF. These
events can be further aggravated by the concomitance of liver dys-
function and a poor nutritional status. Malnutrition is strongly associ-
ated with poor prognosis as assessed by pulmonary function and
survival data [138–140]. The more aggressive nutritional interven-
tions seem to produce better clinical outcomes in these patients and
the possibility of achieving higher antioxidant protection in well-
nourished patients by dietary factors could be a key aspect to explain
such a clinical advantage. The assumption that food-derived compo-
nentsmay help to prevent the damaging effects of oxidative stress im-
proving the antioxidant defenses, deserves further investigation at the
clinical level. This together with the investigation of appropriatelaboratory biomarkers could provide critical information to establish
intervention criteria for an early nutritional management of newly di-
agnosed patients [5]. It is expected that a timely secondary prevention
strategy could inﬂuence the progression of CF symptoms thus
affecting with a self-feeding mechanism the same extent of malnutri-
tion and oxidative stress along the life of CF patients. Since several
factors contribute to impair the nutritional status of CF patients
(such as pancreatic insufﬁciency, chronic malabsorption, recurrent
sinopulmonary infections and progressive lung disease, chronic in-
ﬂammation, increased energy expenditure, suboptimal intake, multi-
therapy) careful monitoring of the antioxidant status should be
recommended. According with international guidelines, fat-soluble
vitamin supplementation is of utmost importance in daily practice to-
gether with energy intake requirements and pancreatic enzyme-
replacement therapy. Among these, vitamin E, β-carotene and ω-3
FA have observed to alleviate selected biochemical signs of oxidative
stress as measured for instance with well established laboratory indi-
ces of lipid peroxidation, and in some studies these effects were
preliminarily associated with positive clinical outcomes. Notwith-
standing, randomized–controlled clinical trials on antioxidant supple-
ments (including ω-3 FA) so far carried out in CF have failed to
conclusively demonstrate signiﬁcant beneﬁcial effects on respiratory
symptoms and on the consequent impact that these have on the qual-
ity of life of these patients (reviewed in [202,213]), whichmay provide
no support for the use of these supplements in CF. An absence of efﬁ-
cacy in prevention studies on antioxidant supplements has also been
observed in other, and possibly less severe, oxidative stress-related
conditions, particularly in the secondary prevention of cardiovascular
disease and some forms of cancer by vitamin E and other antioxidants
such as vitamin C, selenium and β-carotene (reviewed in [163]). Dif-
ferent biases, however, have been identiﬁed in randomize large clini-
cal trials that may account for these disappointing ﬁndings. These
include patient selection criteria (early interventions and primary
prevention could have more chances of success than secondary
prevention), duration and doses of the treatment, use of wrong anti-
oxidant formulations and administration protocols, absence of veriﬁ-
cations of the biological compliance to the treatment, etc. The same
biases apply for the few trials carried out in CF patients. Thus, the ap-
propriateness and efﬁcacy of nutritional interventions with natural
food-derived or synthetic antioxidants should be veriﬁedwith respect
to the biological pathways of oxidative stress and clinical variables
that are identiﬁed as end-points. Proﬁles of blood and tissue antioxi-
dants, as well as of reliable surrogate markers of oxidative stress,
have to be selected and determined in highly specialized laboratories
with a well-established experience on these analyses.
Well-timed (early) interventions with appropriate antioxidant
formulations/protocols need to be proposed for the next generation
of trials, and the development of novel CF-tailored antioxidant and
anti-inﬂammatory agents should be promoted.
As a consequence of these considerations, more clinical investiga-
tion is awaited to identify future successful approaches to the antiox-
idant therapy as a measure to further enhance quality of life and the
overall clinical outcome of CF patients.
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